

(25)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: 0 375 408 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: 22.02.95 (51) Int. Cl. 6: C12N 15/10, C07H 21/04,
 C12Q 1/68, A61K 31/70,
 C12N 15/09
 (13) Application number: 89313391.8
 (22) Date of filing: 20.12.89

Consolidated with 90901460.7/0449972
 (European application No./publication No.) by
 decision dated 22.07.92.

- (54) Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a collinear triplex, the synthetic oligonucleotides and methods of use.

(33) Priority: 20.12.88 US 287359

(43) Date of publication of application:
 27.06.90 Bulletin 90/26

(45) Publication of the grant of the patent:
 22.02.95 Bulletin 95/08

(60) Designated Contracting States:
 AT BE CH DE ES FR GB GR IT LI LU NL SE

(56) References cited:

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 85, no. 5, March 1988, (Baltimore, USA); D. PRASEUTH et al.: "Sequence-specific binding and photocrosslinking of alpha and beta oligodeoxyribonucleotides to the major groove of DNA triple-helix formation", pp. 1349-1353

(73) Proprietor: BAYLOR COLLEGE OF MEDICINE
 One Baylor Plaza
 Houston, TX 77030 (US)

(71) Inventor: Hogan, Michael Edward
 103 Golden Shadow Circle
 The Woodlands
 Texas 77381 (US)
 Inventor: Kessler, Donald Joseph
 3500 Tanglebrush Nr. 3
 The Woodlands
 Texas 77381 (US)

(74) Representative: Lightfoot, Robert Oscar et al
 Raworth, Moss & Cook
 36 Sydenham Road
 Croydon
 Surrey, CR0 2EF (GB)

EP 0 375 408 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

SCIENCE, vol. 238, October 30, 1987 (Washington DC); H.E. MOSER et al.: "Sequence-Specific Cleavage of Double Helical DNA by Triple Helix Formation", pages 645-650

NATURE, vol. 339, no. 6226, June 22, 1989 (New York, London); P. RAJAGOPAL et al.: "Triple-strand formation in the homopurine: homopyrimidine DNA oligonucleotides d(G-A)4 and d(T-C)4", pages 637-640

SCIENCE, vol. 241, July 22, 1988 (Washington DC); M. COONEY et al.: "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene In Vitro", pages 456-459

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 84, no. 15, August 1987 (Baltimore, USA); S.L. BROITMAN et al.: "Formation of the triple-stranded polynucleotide helix, poly (A.A.U)", pages 5120-5124

Description

This invention was supported in part through a grant or award from the National Institute of Health.

The present invention relates generally to a method for making synthetic oligonucleotides which bind to the major groove of a duplex DNA to form a colinear triplex. It also relates to synthetic oligonucleotides which bind to the purine strand of a DNA duplex. It further describes a method of regulating and inhibiting cellular growth by administering a synthetic oligonucleotide which is capable of binding to a DNA duplex to form a colinear triplex.

It has been known for some time that the polynucleotide polydT will bind to the polydA-polydT duplex to form a colinear triplex (Arnott, S & Selsing E. (1974) J. Molec. Biol. 88, 509). The structure of that triplex has been deduced from X-ray fiber diffraction analysis and has been determined to be a colinear triplex (Arnott, S & Selsing E. (1974) J. Molec. Biol. 88, 509). The polydT strand is bound in the parallel orientation to the polydA strand of the underlying duplex. The polydT-polydA-polydT triplex is stabilized by T-A Hoogstein base pairing between A in the duplex and the third strand of polydT. That interaction necessarily places the third strand, called a ligand, within the major groove of the underlying duplex. The binding site in the major groove is also referred to as the target sequence.

Similarly, it has been shown that polydG will bind by triplex formation to the duplex polydG-polydC, presumably by G-G pairing in the major helix groove of the underlying duplex, (Riley M., Mailing B. & Chamberlin M. (1966) J. Molec. Biol. 20, 359). This pattern of association is likely to be similar to the pattern of G-G-C triplet formation seen in tRNA crystals (Cantor C. & Schimmel P., (1988) Biophysical Chemistry vol I, p. 192-195).

Triplexes of the form polydA-polydA-polydT and polydC-polydG-polydC have also been detected (Broitman S., Im D.D. & Fresco J.R. (1987) Proc. Nat. Acad. Sci USA 84, 5120 and Lee J.S., Johnson D.A. & Morgan A.R. (1979) Nucl. Acids Res. 6, 3073). Further the mixed triplex polydCT-polydGA-polydCT has also been observed. (Parseuth D. et al. (1988) Proc. Nat. Acad. Sci. USA 85, 1849 and Moser H.E. & Dervan P.B. (1987) Science 238, 645). These complexes, however, have proven to be weak or to occur only at acid pH.

Parallel deoxyribo oligonucleotide isomers which bind in the parallel orientation have been synthesized (Moser H.E. & Dervan P.E. (1987) Science 238, 645-650 and Rajagopal P. & Feigon J. (1989) Nature 339, 637-640). In examples where the binding site was symmetric and could have formed either the parallel or antiparallel triplex (oligodT binding to an oligoA-oligoT duplex target), the resulting triplex formed in the parallel orientation (Moser H.E. & Dervan P.E. (1987) Science 238, 645-650 and Parseuth D. et al. (1988) PNAS 85, 1349-1353), as had been deduced from x-ray diffraction analysis of the polydT-polydA-polydT triplex.

Studies employing oligonucleotides comprising the unnatural alpha anomer of the nucleotide subunit, have shown that an antiparallel triplex can form (Parseuth D. et al. (1988) PNAS 85, 1349-1353). However, since the alpha deoxyribonucleotide units of DNA are inherently reversed with respect to the natural beta subunits, an antiparallel triplex formed by alpha oligonucleotides necessarily follows from the observation of parallel triplex formation by the natural beta oligonucleotides. For example, alpha deoxyribo oligonucleotides form parallel rather than antiparallel Watson-Crick helices with a complementary strand of the beta DNA isomer.

It has been demonstrated that a DNA oligonucleotide could bind by triplex formation to a duplex DNA target in a gene control region; thereby repressing transcription initiation (Cooney M. et al. (1988) Science 241, 456). This was an important observation since the duplex DNA target was not a simple repeating sequence.

The present invention provides a new method for designing synthetic oligonucleotides which will bind tightly and specifically to any duplex DNA target. When the target serves as a regulatory protein the method can be used to design synthetic oligonucleotides which can be used as a class of drug molecules to selectively manipulate the expression of individual genes.

In accordance with the present invention there is provided a method for making a synthetic oligonucleotide which binds to a target sequence in duplex DNA forming a colinear triplex by binding to the major groove, said method comprising the steps of:

identifying from within genomic duplex DNA a nucleotide target sequence of greater than about 20 nucleotides having either about at least 65% purine bases or about at least 65% pyrimidine bases; and

synthesizing said synthetic oligonucleotide complementary to said identified target sequence, said synthetic oligonucleotide having a G when the complementary location in the DNA duplex has a GC base pair, having a T when the complementary location in the DNA duplex has an AT base pair.

The present invention also provides a synthetic oligonucleotide intended and adapted to bind to an identified target sequence in duplex DNA to form a colinear triplex when the target sequence is either about at least 65% purine bases or about at least 65% pyrimidine bases, comprising:

- 1 a nucleotide sequence containing from about 20 to 40 nucleotides;
- 5 the nucleotide sequence including G and T, wherein G is present when the complementary location in the duplex DNA is a GC base pair and T is present when the complementary location in the duplex DNA is an AT base pair; and
- 10 the sequence being selected from an oligonucleotide orientated 3' to 5' and binding anti-parallel to the about at least 65% purine strand in the duplex DNA target sequence and an oligonucleotide orientated 5' to 3' and binding parallel to the about at least 65% purine strand in the duplex DNA target sequence.
- 15 In the preferred embodiments the synthetic oligonucleotide can have at least one T replaced by X, I, and halogenated derivatives of X and I. Furthermore, at least one G can be replaced with halogenated derivatives of G.
- 20 Additional embodiments include substitutions on the synthetic oligonucleotide. For example, the base can be substituted at the 2' furanose position with a non-charged bulky group and the backbone of the synthetic oligonucleotide can be a phosphodiester analogue which is not readily hydrolyzed by cellular nucleases. In addition, a linker can be affixed at the 3' and/or 5' terminus of the synthetic oligonucleotide. This linker provides a method for attaching modifying groups to the oligonucleotide. The modifying groups can be intercalators, groove-binding molecules, cationic amines and cationic polypeptides.
- 25 In the present specification there is also described a method of inhibiting the growth of cells comprising the step of administering synthetic oligonucleotides in sufficient quantity for cellular uptake and binding to the target sequence, wherein said target sequence is positioned within the DNA domain adjacent to the RNA transcription origin. This procedure can be used to inhibit the growth of cancer cells and pathogens. In one preferred embodiment this procedure is used to inhibit HIV-I virus by binding a synthetic oligonucleotide to the viral LTR region.

In the present specification there is also described a method of altering the relative proportions of the structural protein content of epidermal tissue by administering a synthetic oligonucleotide in sufficient quantity for cellular uptake and binding to target sequences for collagen genes.

Other and further objects, features and advantages will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure when taken in conjunction with the accompanying drawings, in which:-

Fig. 1A shows the surface morphology of a colinear triplex. It is a computer generated rendering of the structure of a duplex DNA target site and presents in both the canonical B and A helix form. Upon binding of an oligonucleotide ligand, the target undergoes a transition from the B to the A form, which creates an increase in the depth of the major helix groove (M). In a colinear triplex, the oligonucleotide wraps about the A form helix target, occupying the major groove. The groove binding has been emphasized by presenting the bound oligonucleotide as a ribbon-like abstraction.

Fig. 1B shows the strand orientation in a colinear triplex. The oligonucleotide ligand binds to the duplex target, in the parallel orientation relative to the orienting (more purine rich) strand.

Fig. 2 shows the pattern of oligonucleotide hydrogen bonding with the duplex target: G to GC sites, T to AT sites. 2A is a computer simulated rendering of the preferred pattern of hydrogen bonding between G in the ligand and G in the GC base pair at the corresponding site within the orienting strand of the duplex target. 2B is an equivalent simulation of T binding to the A of an AT base pair at its corresponding site within the orienting strand of the duplex target. The T-AT association is identical to classical "Hoogstein base pairing", whereas the G-GC association is essentially the quanine counterpart thereof and involves N3 to O6 bonding. Solid wedges define the site at which such a crossection through a triplex is affixed to the corresponding crossection above it. Open wedges define the site at which such a crossection through a triplex is affixed to the corresponding crossection below. As seen, the connectivity defined by the two bonding schemes is nearly identical. It is also important to recognize that the favored pattern of bond formation between G and GC or T and AT (arrows) cannot be mimicked by any other pattern of base-base association at neutral pH (C can mimic G in acid conditions).

2C and 2D are corresponding bonding patterns which result when the G of a GC base pair or A of an AT pair occurs across from the orienting strand of the target duplex. In that instance, the rules of oligonucleotide sequence selectivity are the same (i.e., G at a GC pair, T at an AT pair) however, G bonding occurs N3 to N9 and T bonds in the "reverse Hoogstein" way, thereby both retain the overall parallel orientation of the bound ligand and the orienting strand of the target.

Fig. 3 shows one method of improving the pattern of oligonucleotide hydrogen bonding with the duplex target: xanthine binding to AT sites. The computer generated simulation in Fig. 3 is as in Fig. 2, except

that the effect of substituting xanthine (X) for T is presented. As seen, in both the "Hoogstein" binding (3A and 3B) and "Reverse Hoogstein" (3C and 3D) mode of binding, X and T bind equivalently to an underlying AT base pair. The major difference between the two is that X is nearly identical to the G residues which might flank it in an oligonucleotide ligand, with respect to base size and shape and with respect to the orientation of its phosphodiester component within the oligonucleotide binding site. Modeling predicts that such enhancement of oligonucleotide continuity will enhance the binding affinity and site specificity of all oligonucleotides in which T is replaced by X.

Fig. 4 displays the family of altered phosphodiester linkages compatible with colinear triplex formation. Some of the homologues of the phosphate within the backbone of an oligonucleotide are presented. In each instance, examples are cited which can be prepared by a simple modification of the standard computer assisted, solid phase methods. Examples A-C are thiophosphate linkage, E is methyl-phosphonate, F is phosphoramidite and G is phosphotriester.

Fig. 5 shows formation of hybrid oligonucleotides by means of coupling through a 5' amine linkage. In this instance, a hexylamine linkage is described. This linkage can be affixed as the last residue of an oligonucleotide by employing the same phosphoramidite chemistry used to polymerize the DNA bases. After purification of the linker-modified oligonucleotide, groups which selectively react with a primary alkyl amine can be added. These groups include the isothiocyanate derivative of eosin (EITC) or 9 amino acridine (AA), or any number of other small molecules. Essentially identical chemistry is available for affixing a thiol group to the 5' terminus.

Fig. 6 shows dose dependent inhibition of HIV-1 mRNA by Oligonucleotide mediated DNA tripleplexes. U937/HIV-1 cells [(ATCC CRL 1593, American Type Culture Collection, Rockville, MD), infected with the HTLV-IIIB prototype strain of HIV-1 and cultured under conditions where >90% of the cells remained viable and contained HIV-1 mRNA as shown by *in situ* hybridization with the 35 S-labeled probe for the LTR of HIV-1, (NEP 200, DuPont, Wilmington, DE)] were incubated with each oligonucleotide at 0, 2, 6, 10, and 20 μ M concentrations. Oligonucleotide was added to the culture supernatants at the initiation of incubation and again after 2 hours. Cells were harvested after 4 hours incubation, and washed with PBS before harvest of total cellular RNA using RNazol (Cinna/Biotex Laboratories International, Inc., Friendswood, TX). Serial 2-fold dilutions were made from each RNA preparation (starting at 2.5 μ g RNA) and equal amounts were applied to duplicate nylon membranes using a slot blot apparatus (Biorad). One blot was probed with the radiolabeled EcoR1-Hhal env fragment from the HIV-1 containing plasmid pARV-7/2, while the other was probed with radiolabeled cDNA for β -actin. The resulting autoradiographs were then analyzed by densitometry. The density units expressed on the ordinate express the ratio of (env-probe density) / (actin-probe density). W represent HIV29par, F represent HIV31 anti, and F represent random HIV29 isomer.

Fig. 7 shows the persistence of the effect of oligonucleotides on HIV infected H9 T cells. HIV-1 infected U937 cells were cultured for 12 to 72 hrs. after the last addition of HIV31anti. The oligonucleotide was added at the initiation of the culture and at 2 hrs. thereafter to maintain a final concentration of 10 μ M. Cells were harvested at the indicated time points thereafter. Total cellular RNA was harvested and applied to duplicate nylon membranes in serial dilution with a slot blot apparatus. One replicate was probed with the HIV-1 env cDNA and the other with the cDNA for β -actin. The density units (ordinate) are expressed as the ratio of env to β -actin densitometry readings. F represent HIV31 anti and O represent controls.

Fig. 8 shows inhibition of viral mRNA by HIV29par in infected H9 cells. The densitometric analysis shows a decrease in specific viral message. H9 cells, infected with HTLV IIIB, were treated with oligomer (5 μ M) every two hours. At four and twelve hours the cells were harvested, washed with PBS, and the total cellular RNA was extracted. The hatched bars represent oligomer treatment and unhatched bars represent controls.

The drawings are not necessarily to scale. Certain features of the invention may be exaggerated in scale or shown in schematic form in the interest of clarity and conciseness.

It is readily apparent to one skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope of the invention.

The term "synthetic oligonucleotides as used herein is defined as a molecule comprised of two or more deoxyribonucleotides or ribonucleotides, preferably more than ten. Its exact size will depend on many factors, including its specificity and binding affinity.

When referring to bases herein the term includes both deoxyribonucleic acids and ribonucleic acids. The following abbreviations are used: "A" refers to adenine as well as its deoxyribose derivatives, "T" refers to thymine as well as its deoxyribose derivative, "G" refers to quanine as well as its deoxyribose derivative, "C" refers to cytosine as well as its deoxyribose derivative, "X" refers to xanthine as well as its

deoxyribose derivative and "I" refers to inosine.

The "major groove" refers to one of the grooves along the outer surface of the DNA helix which is formed because the sugar-phosphate backbone extends further from the axis than the bases do. The major groove is important for binding of regulator molecules to specific DNA sequences.

5 A set of procedures have been established to design DNA or RNA oligonucleotides which bind specifically to a DNA target by colinear triplex formation. One embodiment of the present invention is a method for making a synthetic oligonucleotide which binds to a target sequence in duplex DNA forming a colinear triplex by binding to the major groove, said method comprising the steps of: scanning genomic duplex DNA and identifying nucleotide target sequences of greater than 20 nucleotides, said target
10 sequences having either about at least 65% purine bases or about at least 65% pyrimidine bases; and synthesizing said synthetic oligonucleotide complementary to said identified target sequence, said synthetic oligonucleotide having a G when the complementary location in the DNA duplex has a GC base pair, having a T when the complementary location in the DNA duplex has an AT base pair. In specific embodiments the synthetic oligonucleotide is selected from the group consisting of an oligonucleotide oriented 3' to 5' and binding anti-parallel to the about at least 65% purine strand and an oligonucleotide oriented 5' to 3' and binding parallel to the about at least 65% purine strand. The resulting oligonucleotide can be synthesized in gram quantities by the standard methods of solid phase oligonucleotide synthesis.

15 The site-specific oligonucleotide procedure is divided into three parts:

I. Oligonucleotide base sequence design.

- 20 II. Analysis of the duplex target
III. Secondary chemical modification of the oligonucleotide.

I. Oligonucleotide base sequence design.

25 After identifying a DNA target with an interesting biological function, an oligonucleotide length must be chosen. There is a one to one correspondence between oligonucleotide length and target length. For example, a 27 base long oligonucleotide is required to bind to a 27 base pair long duplex DNA target. Under optimal conditions, the stability of the oligonucleotide-duplex DNA interaction generally increases continuously with oligonucleotide length. In the preferred embodiment, a DNA oligonucleotide in the range
30 of about 20 to 40 bases is used. Oligonucleotides in this range usually have useful dissociation constants for their specific DNA target. The dissociation constants are preferably in the range of about 10^{-9} to 10^{-8} molar.

Oligonucleotides shorter than 20 bases display weaker and less specific binding to the target sequence and are thus less useful.

35 Oligonucleotide binding to duplex DNA is stabilized by binding to the purines in the underlying duplex. Once a DNA target has been identified, the more purine rich strand of the target area is defined as the "orienting" strand of the binding site. An oligonucleotide ligand was designed to bind either parallel or anti-parallel to the orienting strand. The stability of the binding is dependent on the size of the oligonucleotide and the location in the genome. Sometimes the parallel is more stable than the anti-parallel while at other
40 times the reverse is true or they are equally stable. In the preferred embodiment the method of designing a detailed sequence of an oligonucleotide ligand involves placing a T in the oligonucleotide whenever an AT base pair occurs in the duplex target, and placing a G in the oligonucleotide whenever a GC base pair occurs in the duplex target.

45 Examples of the orientation of bond donors and acceptors based on this oligonucleotide structure is displayed in Figures 2 and 3.

Another embodiment of the present invention includes a synthetic oligonucleotide for forming a colinear triplex with a target sequence in a duplex DNA when said target sequence is either about at least 65% purine bases or about at least 65% pyrimidine bases, comprising, a nucleotide sequence of at least about 20 nucleotides; said nucleotide sequence including G and T, wherein G is used when the complementary
50 location in the duplex DNA is a GC base pair and T is used when the complementary location in the duplex DNA is an AT base pair; and said sequence selected from the group consisting of an oligonucleotide oriented 3' to 5' and binding anti-parallel to the about at least 65% purine strand in the duplex DNA target sequence and an oligonucleotide oriented 5' to 3' and binding parallel to the about at least 65% purine strand in the duplex DNA target sequence. Although molecules which include one or more bases which do not comply with this relationship can be fabricated, the binding affinity and site specificity of these altered oligonucleotides will be reduced. Consequently the biological potency of these molecules will be inferior to the oligonucleotides having the G/GC and T/AT relationships.

EP 0 375 408 B1

Below is a schematic which demonstrates a target sequence, and oligonucleotides ligands which have been designed by the above design procedure.

Target Sequence (35bp)

5'-GGGAATTGGCGGGTAAATTCGGGATAGGCCTAA-3'

5 3'-CCCTAACCGCCCATTAAAGCCCTATCCGCCATT-5'

Parallel Synthetic Oligonucleotide

5'-GGGTTTTGGGGGGTTTTGGGGTTGGGGTTT-3' (par)

Anti-Parallel Synthetic Oligonucleotide

3'-GGGTTTTGGGGGGTTTTGGGGTTGGGGTTT-5' (anti)

10 If the synthetic oligonucleotide is constructed with a standard phosphodiester linkage, its binding affinity for the target would be near 10^{-8} M under physiological conditions of salt, divalent ion concentration and temperature. Since the dissociation constant for oligonucleotide binding to a random DNA sequence population is near 10^{-3} M for a 35 base oligonucleotide, the synthetic oligonucleotide affinity for the target would be approximately 10^5 times greater than for random sequence DNA under the same conditions.

15

II. Analysis of the duplex target.

If these procedures are followed to make a synthetic oligonucleotide, any duplex DNA sequence of about at least 65% purines can form a stable triplex. Within a DNA region, although the A + T content is not a significant consideration, duplex DNA sequences which have only purines on the template strand form complexes which in general, are characterized by enhanced stability. If we define n as the number of bases within the template strand which are purine and define (1-n) as the number of pyrimidine bases in the template, then the approximate dissociation constant can be predicted from the following semi-empirical formula:

25

$$K = \exp^{-[0.4n + (0.2(1-n)/RT)]}$$

This formula assumes near-physiological conditions in vitro, that is 0.05 M TRIS/HCl, 5mM MgCl₂, 3mM spermine pH 9.2, 37 °C. These conditions constitute the operating standard used in the design process.

30 This relationship predicts that an oligonucleotide designed to bind a 35 base long target sequence containing only purine bases in its template strand will form a triplex in which the oligonucleotide binds with a standard dissociation constant of about 1×10^{-10} M. This dissociation constant will be altered, however, when pyrimidine is in the template strand. In the above schematic representation where the template contains pyrimidine, the dissociation constant is 3×10^{-7} M.

35 This relationship is consistent with the observation that the free energy of triplex formation appears to increase in proportion to the span of the target-oligonucleotide interaction and the observation that the binding energy of a G to a GC base pair or a T to an AT base pair is dependant on base pair orientation relative to the template strand.

The molecular origin of that effect can be seen in Figure 2. It is evident that when the underlying 40 template strand comprises a series of purines, the bases in the complementary third strand form a contiguous stacked array. On the other hand, placing a pyrimidine in the template strand inverts the base pair. Thus, although third strand hydrogen bonding still occurs with parallel strand orientation, it is associated with a dislocation of the path traversed by the third strand in the major groove. Thus for either an AT or GC base pair, approximately 0.4 kcal of favorable binding free energy results from third strand 45 association at a purine site in the template, but only approximately 0.2 kcal when the third strand binds to a site at which a purine to pyrimidine inversion has occurred.

III. Secondary chemical modification of the oligonucleotide.

50 A. One skilled in the art will recognize that a variety of synthetic procedures are available. In the preferred embodiment the oligonucleotides are synthesized by the phosphoramidite method, thereby yielding standard deoxyribonucleic acid oligomers.

Molecular modeling suggests that substitution of the non-hydrolyzable phosphodiester backbone in the oligonucleotide at elected sites will actually enhance the stability of the resulting triplex. The phosphodiester analogues are more resistant to attack by cellular nucleases. Examples of non-hydrolyzable phosphodiester backbones are phosphorothioate, phosphoroselenoate, methyl phosphate, phosphotriester and the alpha enantiomer of naturally occurring phosphodiester. The thiophosphate and methyl phosphonate linkages are shown in Fig. 4. These non-hydrolyzable derivatives of the proposed

oligonucleotide sequences can be produced, with little alteration of DNA target specificity.

Backbone modification provides a practical tool to "fine tune" the stability of oligonucleotide ligands inside a living cell. For example, oligonucleotides containing the natural phosphodiester linkage are degraded over the course of 1-2 hours in eukaryotic cells, while the non-hydrolyzable derivatives appear to be stable indefinitely.

5 B. Oligonucleotide hybrids provide another method to alter the characteristics of the synthetic oligonucleotides. Linkers can be attached to the 5' and/or 3' termini of the synthetic oligonucleotide. The linkers which are attached to the 5' terminus are usually selected from the group consisting of a base analogue with a primary amine affixed to the base plane through an alkyl linkage, a base analogue with a sulfhydryl affixed to the base plane through an alkyl linkage, a long chain thiol coupled directly to the 5' hydroxyl group of the oligonucleotide and a long chain amine coupled directly to the 5' hydroxyl group of the oligonucleotide. The linker on the 3' terminus is usually a base analogue with a primary amine affixed to the base plane through an alkyl linkage or a base analogue with a sulfhydryl affixed to the base plane through a alkyl linkage. Affixation of a primary amine linkage to the terminus does not alter oligonucleotide binding to the duplex DNA target.

10 Once a linkage has been attached to the synthetic oligonucleotide a variety of modifying groups can be attached to the synthetic oligonucleotide. The molecules which can attach include intercalators, groove-binding molecules, cationic amines or cationic polypeptides. The modifying group can be selected for its ability to damage DNA. For example, the modifying group could include catalytic oxidants such as the iron-EDTA chelate, nitrogen mustards, alkylators, photochemical crosslinkers such as psoralin, photochemical sensitizers of single oxygen such as eosin, methylene blue, acridine orange and 9 amino acridine and reagents of direct photochemical damage such as ethidium and various pyrene derivatives.

15 For example an "aminolink", as supplied by Milligen (see Figure 5) works nicely. However, terminal coupling of any sort is likely to be equivalent. Once synthesized with an aminolink, the modified oligonucleotides can be coupled to any reagent which is specific for a primary amine, for example a succimidate or isothiocyanate moiety (Fig. 5).

20 In one embodiment, an "aminolink" coupling is used to affix the intercalating dyestuff 9 acridine isothiocyanate to triplex forming oligonucleotides. The duplex binding affinity of the oligonucleotide-dye hybrid is approximately 100-fold greater than the oligonucleotide binding affinity. Other embodiments include affixing eosin isothiocyanate to oligonucleotides. Since eosin isothiocyanate cleaves the DNA helix upon irradiation this hybrid oligonucleotide cuts the helix at its binding site when irradiated. This hybrid-oligonucleotide is useful for identifying the oligonucleotide binding site both in vitro and in vivo and potentially can be used as a therapeutic tool for selective gene target destruction.

25 Photochemical reactivity is also achieved by affixation of psoralin derivatives to oligonucleotides through a 5' linkage. Psoralin binds covalently to DNA after irradiation, and as a consequence is a potent cytotoxic agent. Thus, photochemical reactivity, with oligonucleotide sensitivity provides a tool to direct the toxic psoralin lesion to the oligonucleotide target site.

30 Similar oligonucleotide coupling is used to target toxic chemical reactivity to specific DNA sequences. Examples include catalytic oxidants such as transition metal chelates and nucleases.

35 Photochemical reactivity and/or toxic chemical agents can be used to permanently inhibit gene expression.

In addition to chemical reactivity, modifications of oligonucleotides alter the rate of cellular uptake of the hybrid oligonucleotide molecules. The uptake process is rapid, but poorly understood. Terminal modification provides a useful procedure to modify cell type specificity, pharmacokinetics, nuclear permeability, and absolute cell uptake rate for oligonucleotide ligands.

40 C. Modified base analogues provide another means of altering the characteristics of the synthetic oligonucleotide. Although a purine rather than a pyrimidine, X is identical to T with respect to its capacity to form hydrogen bonds. Molecular modeling has shown that substitution of X for T in the above oligonucleotide design procedures, results in a modified triplex that is much more stable. The increased stability is due principally to enhanced stacking and to an enhancement of phosphodiester backbone symmetry within the ligand. Examples of base substitutions for T are X, I and halogenated X and I. G can be replaced by halogenated G. Furthermore, the 2' furanose position on the base can have a non-charged bulky group substitution. Examples of non-charged bulky groups include branched alkyls, sugars and branched sugars. In the preferred embodiment at least one base is substituted.

45 Molecular modeling suggests that oligonucleotide design will produce ligands with target affinity and specificity which exceeds that of even the most specific antigen-monoclonal antibody interaction.

EP 0 375 408 B1

Synthetic oligonucleotides have been designed to the transcription control region of the human c-myc protooncogene, to the regulation sequence of collagen Ia, to bind to the TATA box segment of the chicken alpha actin gene, and to bind to an enhancer sequence within the early gene region of human HIV-I.

In the present specification there is described a method of inhibiting the growth of cells, comprising the step of administering a synthetic oligonucleotide in sufficient amount for cellular uptake and binding to the target sequence, wherein said target sequence is positioned within the DNA domain adjacent to the RNA transcription origin. The synthetic oligonucleotide is as described above in the description of the design process. Uptake into the cells is rapid for these synthetic oligonucleotides and can be altered with the appropriate substitutions and modifications. Similarly the binding can be altered by appropriate changes to the synthetic oligonucleotide. The inhibition of cell growth can be used in the treatment of cancerous cells. Additions of the specific oligonucleotide will selectively inhibit cell growth. For example synthetic oligonucleotides to the c-myc gene can be used to inhibit some cancerous cell growth. Examples of synthetic oligonucleotide which inhibit c-myc expression include: 3'-TGGTGTGTGGGTTTG' and/or 3'-GGGTGGGGGGTTTTGGGTGGG-5'
and/or 3'-TGTGGTGGGGTGGTTGGGGTGGGTGGGTGGG-5'
and/or 5'-TTGGTGTGGGGTGGGGTGGGTGGGTGGG-5'
and/or 5'-GGTTGGGGTGGGTGGGGTGGGTGGG-3' and fragments and analogues thereof.

Another embodiment includes a method of inhibiting the growth of pathogens comprising the step of administering a synthetic oligonucleotide in sufficient amount for cellular uptake and binding to the target sequence, wherein said sequence binds within the nucleic acid domain adjacent the RNA transcription origin. For example HIV-1 virus can be inhibited with a synthetic oligonucleotide which selectively binds to the viral LTR region. Specific examples of this synthetic oligonucleotide can include 3'-GTTTTGGGTGTTGTGGGTGTGGTT-5'
and/or 5'-TGGGTGGGGTGGGTGGGGGTGTGGGGTGTGGGGT-3' and fragments and analogues thereof.

An additional embodiment includes a method of manipulating the structural protein content of epidermal tissue comprising the step of administering a synthetic oligonucleotide in sufficient amount for cellular uptake and binding to the target sequence. This includes inhibiting the various enzymes and regulating proteins in skin. For example, the collagen Ia gene synthesis rate can be altered by using 3'-TGGGTTGGGTGGTGGGGGTGTGGTTGGGTGG-5'
and/or 3'-GTGGGTTGGGTGGTGGTGGGGGTGTGGTTGG-5' and fragments and analogues thereof as the synthetic oligonucleotide. Similarly the collagenase gene can be inhibited by using 5'-GGTTGGGGTGGTGTGGTTGGGTGG-3' and/or 5'-TTGTGGTGTGGTTGGGTGTGGTGTGGTGTGG-3', and fragments and analogues thereof.

The following examples are offered by way of illustration and are not intended to limit the invention in any manner. The synthetic oligonucleotides described in the examples can include any of the substitutions discussed earlier. The backbone, base, linkers and modifying groups can be added. These substitutions will enhance the affinity, the chemical stability, and the cellular uptake properties of the specific oligonucleotide treatments.

40 Example 1.

A. A Method For Arresting the Growth of Cancerous Tissue in Man, by Means of Intervention into the Program of c-myc Gene Expression.

45 Available evidence suggests that a family of tumors, including Burkitt's lymphoma and others, share a common genetic lesion, which is evident as constitutive overproduction of the c-myc mRNA and its corresponding c-myc protein. Because the c-myc protein has been shown to be a critical element in the control of cell growth, it is believed that there may be a direct causal relation between the overproduction of c-myc protein and uncontrolled cancerous growth for such cells.

50 In both cancerous and normal cells, the c-myc gene possesses several target sequences within its 5' flanking sequence which satisfy the synthetic oligonucleotide design criteria. In a program of drug development, these target sequences and others are used as templates to direct oligonucleotide design. The purpose of these oligonucleotides is to selectively inhibit c-myc transcription, thereby repressing the uncontrolled growth of tumors with the c-myc lesion.

55 Three representative target sequences in the transcription control region of the human c-myc gene are shown below:

EP 0 375 408 B1

A. TARGET: THE TATA BOX FOR THE C-MYC GENE

DNA TARGET DUPLEX

5 -61 -16
5' -TCCTCTCTCGCTAATCTCCGCCACCGGCCTATAATGCGAGGG-3'
3' -AGGAGAGAGCGATTAGAGGC~~GGGT~~GGCCGGAAATATTACGCTCCC-5'

10 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TGGTGTGTGGGTTTGTTGGGGGGTTTTGGGTGGG-5'
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TGGTGTGTGGGTTTGTTGGGGGGTTTTGGGTGGG-3'

15 B. TARGET: TRANSCRIPTION ACTIVATOR BINDING SITE - THE PRINCIPAL ACTIVATING PROTEIN
BINDING SITE OF THE C-MYC GENE PROMOTER

Inappropriately high levels of c-myc gene expression are strongly associated with the incidence of a
20 variety of human tumors. The triplex oligonucleotides described here were designed to selectively repress
the expression of the c-myc gene in such tumors, thereby slowing tumor growth.

(1) DNA TARGET DUPLEX

25 -153 -116
5' -TCTCCTCCCCACCTTCCCCACCCCTCCCCACCC~~T~~CCCCA-3'
3' -AGAGGAGGGGTGGAAGGGTGGGAGGGTGGGAGGGT-5'

30
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE
5'-GTGGTGGGTGGTGGGTGGGTGGGTGGGTGGGT-3 (GT37anti)

35 (2) DNA TARGET DUPLEX

-153 -116
40 5' -TCTCCTCCCCACCTTCCCCACCC~~T~~CCCCACCC~~T~~CCCCA-3'
3' -AGAGGAGGGGTGGAAGGGTGGGAGGGTGGGAGGGT-5'

45 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'- GTGGTGGGTGGTGGGTGGGTGGGTGGGT-5'

(3) DNA TARGET DUPLEX (27bp)

50 -142 -115
5' -CCTTCCCCACCC~~T~~CCCCACCC~~T~~CCCCA-3'
3' -GGAAGGGGTGGGAGGGTGGGAGGGT-5'

55

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGTTGGGTGGGTGGGTGGGTGGGT-5' (par)

ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE

5'-GGTTGGGGTGGGTGGGGTGGGTGGGGT-3' (anti)

The 27 bp target duplex has 74% GC base pairs and 89% purine on the orienting strand. The Kdiss (6×10^{-10} M) is the same for both the parallel and anti-parallel binding.

5

C. TARGET: SEQUENCE BETWEEN TATA BOX AND ACTIVATOR SITE IN A HIGHLY CONSERVED SEQUENCE AMONG THE VERTEBRATE c-myc GENE FAMILY.

DNA TARGET DUPLEX

10

-87

-58

5' -AAAGCAGAGGGCGTGGGGAAAAGAAAAAAGA-3'

15

3' -TTTCGTCTCCCGCACCCCCCTTTCTTTTCT-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

5'-TTTGGTGTGGGGGTGGGGTTTGTTTTGT-3'

20 ANTIPARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

3'-TTTGGTGTGGGGGTGGGGTTTGTTTTGT-5'

The likely function of these sites, the position relative to the RNA transcription origin, and the oligonucleotide sequence which can be used as a c-myc specific treatment are shown. One skilled in the art will readily recognize that as the molecular genetics of the c-myc gene is elucidated in greater detail, the 25 list of target sequences within the 5' flanking region will be expanded, by application of the above design criteria.

Both synthetic oligonucleotides A and B specifically interact within the target duplex to inhibit tumor growth, by means of specific repression of c-myc transcription. The specific method of inhibition of oligonucleotide C is unknown.

30 One skilled in the art will readily recognize that oligonucleotides for other genes involved in human tumors can be similarly designed. The procedure is only limited by the available molecular sequence data.

Example 2.

35 A Method for Manipulating the Structural Protein Content of Epidermal Tissues, for the Purpose of Altering Tissue Appearance and Wound Healing.

The structural proteins which define the mechanical properties of skin are well known. The molecular structure of the collagen and elastin proteins and their corresponding proteases, collagenase and elastase, 40 have been intensley studied. These proteins are under the control of an elaborate program of regulation, which appears to change during the wound healing process and as a result of the aging process. The molecular structure is sufficiently defined to consider treatments based upon gene-specific intervention into the pattern of structural protein synthesis and/or enzymatic degradation.

Data suggest that the change in the mechanical properties of skin which accompanies aging (wrinkling, 45 etc.) is due in part to an age-specific change in the relative abundance of the collagens and other structural proteins. Interference with the synthesis and/or selective degradation of these proteins by drug treatment can reestablish a distribution which approximates that of younger tissue, and thus the effects of aging can be partially reversed.

A program of synthetic oligonucleotide design, based upon manipulation of collagen I synthesis in 50 human skin is described below. By altering the relative protein concentrations the structure and mechanical properties of skin can be altered. Thus the synthetic oligonucleotide can be used as a therapeutic agent to alter the skin aging process or to alter the wound healing process. One skilled in the art will readily recognize that the concepts can be extended to other collagens, to other skin proteins and to their complementary proteases based upon the availability of the necessary genetic data.

55 Representative target sequences in the transcription control region of the human alpha 1(I) collagen gene, the likely function of those sites, their position relative to the RNA transcription origin, and the synthetic oligonucleotide sequence designed for collagen specific treatment are shown below. As the molecular genetics of the collagen gene develops, the list of target sequences within the 5' flanking region

will be expanded.

A. TARGET: THE CAT BOX FOR THE COLLAGEN GENE

5 DNA TARGET DUPLEX

10 -168 -124
5' -TCCCTTCCCTCCTCCTCCCCCTCTCCATTCCAACTCCAAATT-3'
3' -AGGAAGGGAGGAGGAGGGGAGAGGTAAGGTTGAGGGTTAA-5'

15 SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGGTTGGGTGTGGTTGGGTGGGGTTGG-5'

B. TARGET: ENHANCER FOR THE COLLAGEN GENE

DNA TARGET DUPLEX

20 -294 -264
5' -CCCTACCCACTGGTTAGCCCACGCCATTCT-3'
3' -GGATGGGTGACCAATCGGGTGCGGTAAGA-5'

25 SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGGTTGGGTGTGGTTGGGTGGGGTTGG-5'

30 C. TARGET: HIGHLY CONSERVED POLYPURINE SEGMENT WHICH OCCURS NEAR -200 IN ALL
COLLAGENS

DNA TARGET DUPLEX

35 -177 -136
5' -CTCCCTTCCCTCCTCCTCCCCCTCTCCATTCC-3'
3' -GAGGAAGGGAGGAGGAGGGGAGAGGTAAGG-5'

40 SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GTGGGTTGGGTGGTGGTGGGGGTGTGGTTGG-5'

45 Synthetic oligonucleotides A and B inhibit type I collagen protein synthesis. The process includes the specific repression of collagen RNA transcription. The method of inhibition of the C synthetic oligonucleotide is not known. The effect on protein synthesis of skin proteins can be seen by adding sufficient amounts of the synthetic oligonucleotide for uptake into cultured human fibroblasts.

Next, two representative target sequences are described in the transcription control region of the human collagenase gene, the function of these sites, their position relative to the RNA transcription origin, and the oligonucleotide sequence designed as a collagen specific treatment. As the molecular genetics of the 50 collagenase gene develops, the list of target sequences within the 5' flanking region will be expanded.

D. TARGET: THE TATA BOX FOR THE COLLAGENASE GENE

DNA TARGET DUPLEX

5 -48 -16

10 5' -GGAAGGGCAAGGACTTTATATATACAGAGGGAG-3'
3' -CCTTCCCGTTCCCTGAGATATATATGTCTCCTC-5'

SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGTTGGGGTTGGTGTGTGTGTGGGTG-3'

E. TARGET: THE INDUCIBLE ENHANCER FOR THE COLLAGENASE GENE. CONFERS TPA TUMOR PROMOTOR RESPONSIVENESS.

DNA TARGET DUPLICATES

**SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTGTGGTTGTTTTTTGGTTGTGTGT-3'**

The D synthetic oligonucleotide inhibits collagenase protein synthesis. The process includes specific repression of collagenase RNA transcription. The E synthetic oligonucleotide causes loss of TPA sensitivity, and a subsequent repression of collagenase syntheses in the presence of promoters such as TPA. This process includes specific repression of collagenase RNA transcription. Synthetic oligonucleotide interaction will cause collagen protein levels in the cell to rise, as collagenase levels fall. The clinical effect of the increase should cause a useful alteration of the mechanical properties of skin. The effects can be seen by adding sufficient amounts of oligonucleotide for cellular uptake to cultured human fibroblasts.

One skilled in the art will readily appreciate that these concepts can be extended to other genes which are known to be involved in skin development, repair and aging and is only limited by the available molecular genetic data.

40

Example 3

A Method to Repress the Growth of Human HIV-1 Virus, by means of Oligonucleotide Binding to Target Sites within the HIV-1 LTR.

45 The HIV-1 virus is known to be the causative agent in human acquired immune deficiency syndrome (AIDS). The long terminal repeat of the HIV-1 virus is known to possess several DNA segments within the LTR region which are required for transcription initiation in a human T-cell host. The synthetic oligonucleotides selectively repress HIV-1 mRNA synthesis in a human host cell, by means of triplex formation upon target sequences within the viral LTR. Repression of an RNA synthesis results in the reduction of the growth rate of the virus. This could result in the slowing of the infection process or the repression of the transition from latency to virulent growth. Most of the sites within the LTR will comprise target sites for drug (oligonucleotide) intervention. There is no wasted DNA in the small, highly conserved LTR region.

55 Representative target sequences in the transcription control region of the human HIV-1 LTR, the likely function of these sites, their position relative to the RNA transcription origin, and the oligonucleotide sequence designed as a HIV-1 specific treatment are shown below. As the molecular genetics of HIV-1 develops, the list of target sequences within the LTR and elsewhere will be expanded.

EP 0 375 408 B1

In all instances, both the parallel and antiparallel isomers are described. The reason is that, although one or the other will always display the better binding affinity in vitro, the efficacy of each must be tested in vivo to make the final decision.

5 A. TARGET: THE 5' END OF THE HIV-1 LTR DOMAIN

DNA Target Duplex (25bp, 92% Purine)

10 -470 -446
5' -AAAAGAAAAGGGGGGACTGGAAGGG-3'
3' -TTTCTTTCCCCCTGACCTCCC-5'

15 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

5'-TTTGTTTGGGGGTGTGGTTGG-5' (HIV1par)

ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

3'-TTTGTTTGGGGGTGTGGTTGG-5' (HIV1anti)

20 B. TARGET SITE: A segment of the negative HIV1 regulatory domain, with similarity to a homologous domain in interleukin 2 gene.

DNA Target Duplex (33bp, 88% purine)

25 -293 -261
5' -AGAGAAGGTAGAACAGGGCCAATGAAGGAGAGAA-3'
3' -TCTCTCCATCTCTCCGGTTACTCCTCTCTT-5'

30 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

5'-TGTGTTGGTTGTTGTGGGTTGTTGGTGTGTT-3' (HIV2par)

ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

3'-TGTGTTGGTTGTTGTGGGTTGTTGGTGTGTT-5' (HIV2anti)

35 C: TARGET SITE: A site near the center of the LTR.

DNA Target Duplex (25bp, 88% purine)

40 -229 -205
9327 9351
5' -GGGATGGAGGACGCAGAAAGAAG-3'
45 3' -CCCTACCTCCTGCGCCTCTTC-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

5'-GGGTTGGTGGTGGGGGTGTTGTTG-3' (HIV3par)

50 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

3'-GGGTTGGTGGTGGGGGTGTTGTTG-5' (HIV3anti)

D. TARGET SITE:

55 Binding site for the Sp1-line transcription activator.

(1) DNA Target Duplex (36bp, 78% purine)

10 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGGGTGGGGTGGGTGGGGGTTGGGGGTTG-3' (HIV4par) or (HIV36par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGGGTGGGGTGGGTGGGGGTTGTCCTCTGGGG-5' (HIV4anti) or (HIV36anti)
The HIV4 par also functions if TG is added to the 3' end to make HIV38 par.

E. TARGET: BINDING SITE FOR THE TRANSCRIPTION ACTIVATOR REGION (*tar*); THE DOWNSTREAM MALE LOCUS (DSL)

DNA TARGET DUPLEX (69-81 bp - 72%)

-16 +13
5'-CTTTTGCCTGTACTGGGTCTCTCTGGTTAG-3'
3'-GAAAAAACGGACATGACCCAGAGAGACCAATC-5'

The oligonucleotides, HIV29par and HIV31anti, were designed as previously described herein. HIV31anti also functions if bases two TG are removed from the 3' end. The relative mobility and DNA footprint analyses of both oligonucleotides show binding with high affinity to target proviral sequences, *in vitro*.
 HIV-1 infected U937 cells, a monocytoid line, were treated with up to 20 μ M with either HIV29par, HIV31anti, or a random isomer of HIV29 with no detectable *in vitro* affinity for the target sequence. Significant inhibition of viral mRNA production, as shown by the decrease in the relative concentrations of env as compared to β -actin mRNA, was achieved at a dose of 10 μ M of either oligonucleotide ($p < .01$, paired t-test, figure 6). No additional suppression was observed at 20 μ M. The random isomer of HIV29 did not inhibit viral mRNA synthesis, even at 20 μ M, confirming the specificity of the suppression achieved with HIV29.
 We found that when HIV-1 infected U937 cells were treated with 10 μ M of either HIV29par or HIV31anti, the relative concentration of env mRNA decreased to approximately 50% of control levels (figure 6). This effect was dose-dependent, as the relative concentration of env mRNA decreased to approximately 70% of control levels at 20 μ M of either oligonucleotide. The random isomer of HIV29 had no effect on the relative concentration of env mRNA at 20 μ M.

We found that when U937/HIV-1 cells were incubated in media containing 0.6 μ M 32 P-labeled HIV29par, the cells were able to rapidly sequester the oligomer in concentrations exceeding that of the media. Assuming an average cell volume of 350 fL, it was determined that the intracellular concentration increased from 2.4 μ M after 10 minutes to a plateau of about 6 μ M after 2 hours. The oligonucleotides had a prolonged effect on HIV-1 transcription in that two treatments, spaced two hours apart, inhibited viral mRNA synthesis for up to 72 hrs (figure 7). Further studies showed the effect of tar sequence specific oligonucleotides on infected T cells. HIV29par was used to treat HIV-infected H9 T cells. Treatment every 2 hrs. with 5 μ M effectively suppressed mRNA synthesis in HIV-1 infected H9 T cells at 2 and 12 hours.

Thus, the evidence shows that the oligonucleotides designed to bind within the major groove of the DNA helix, and form triplexes with specific gene sequences in the tar region of the HIV-1 provirus are readily taken up by HIV-1 infected cells and selectively suppress synthesis of HIV-1 mRNA without concomitant suppression of mRNA for β -actin, which constitutive expressed in these cells. With inhibition of viral mRNA synthesis, translation of virus-encoded proteins is also suppressed. Inhibition of viral mRNA depended on the dose of oligonucleotide added; maximum inhibition occurred at concentrations $\geq 10\mu M$. The oligonucleotides designed to bind to specific sequences in the DNA duplex and form colinear triplex with the targeted sequences provide an efficient and highly specific agent for regulating gene expression, such agents provide a new class of rationally designed chemotherapeutic agents for controlling virus

EP 0 375 408 B1

replication and other processes depend upon new mRNA production.

The synthetic oligonucleotides in A through E will inhibit HIV-1 mRNA synthesis, hence viral growth. The process includes specific repression of RNA transcription from the viral LTR.

One skilled in the art will readily recognize that these concepts can be extended to other genes which are known to be involved in the infection process by which HIV-1 and other viruses act.

Example 4

A Method for Altering Chicken Skeletal Actin Transcription

10 A representative target sequence in the transcriptions control region of the chicken skeletal alpha actin gene, the function of that site, its position relative to the RNA transcription origin, and the oligonucleotide sequence which would be designed as an actin specific treatment are shown below. As the molecular genetics of the actin gene develops, the list of target sequences within the actin control region will be expanded.
15

A. TARGET: THE TATA BOX FOR THE CHICKEN SKELETAL ALPHA ACTIN GENE

DNA TARGET DUPLEX

20 -30 -4
 5' - GATAAAAGGCTCCGGGGCCGGCGGCGG-3
 3' - CTATTTCCGAGGCCCGGCCGCC-5'

SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GTTTAACTGGGTGGGGGGGGGGGGGGGGGG-3'

This synthetic oligonucleotide molecule inhibits actin protein synthesis, by specific repression of RNA transcription. This inhibition can be assessed in cultured chicken myoblasts. The intact chicken will show a change in the quality of actin and other muscle proteins whose synthesis is strongly coupled to actin expression. The practical result of this change will be an alteration of the properties of chicken meat.

One skilled in the art will readily appreciate that these concepts can be extended to other genes which are known to be involved in muscle growth and development, and is limited by the available molecular genetic data.

Example 5

INTERLEUKIN 2 ALPHA CHAIN RECEPTOR

**TARGET: TRANS PROMOTOR REGION
DNA Target Duplex (28bp)**

-273 **-246**
45 5'-AACGGCAGGGGAATCTCCCTCTCTTTT-3'

3' -TTGCCGTCCCTTAGAGGGAGAGGAAAA-5'

50

Parallel Synthetic Oligonucleotide
5'-TTGGGGTGGGGTTTGTGGGTGTGGTTTT-3' (IL28par)

Anti-Parallel Synthetic Oligonucleotide

The 28bp target is comprised of 54% G+C base pairs and is 61% purine on the orienting strand. The Kd_{eq} for the parallel strand is 1.5×10^{-7} and the Kd_{eq} for the antiparallel is 9.0×10^{-7} .

EP 0 375 408 B1

Example 6

A Sequence For Dispersing Plaque Formation in Alzheimers Disease

- 5 The APP770 Gene Promotor is the precursor protein responsible for production of plaque in Alzheimers disease.

A. TARGET SITE: DOWNSTREAM TATA BOX SITE

- ## 10 DNA Duplex Target

-712 -679

5' -AAAAACAAACAAAAATATAAGAAAGAAACAAAAA-3'

3' -TTTTTGTTGTTTATATTCTTTCTTTGTTT-5'

**PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTTTTGTTGTTTCTTTCTTT-3' (APP1par)**

- 20 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TTTTTGTTTGTTTTTTTCTTTCTTTCTTT-5' (APP1anti)

B. TARGET: UNKNOWN

- ## 25 DNA Duplex Target

-618 -590

5' -TCCTGCGCCTGCTCCTTGGTTGTTCT-3'

3' -AGGACGCGAACGAGGAAACCAAGCAAGA-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TGGTGGGGGTTGGTGGTTGGTTGGTGT-5' (APP2par)

- 35 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TGGTGGGGGTTGGTGGTTGGTTGGTTGT-3' (APP2anti)

C. TARGET: UNKNOWN

- ## 40 DNA Duplex Target

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TTGTGTTGTTGGTGGTGGTGGTGGTGGTGG-5' (APP3par)
50 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTGTGTTGTTGGTGGTGGTGGTGGTGGTGG-3' (APP3anti)

EP 0 375 408 B1

D. TARGET: UNKNOWN

DNA Duplex Target

5 -434 -407
5' -GAGAGAAAAACGAAATGCGGATAAAAAA-3
3' -CTCTCTTTTTGCTTACGCCTATTTT-5

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GTGTGTTTTGGTTTGGGGTTTTT-3' (APP4par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
15 3'-GTGTGTTTTGGTTTGGGGTTTTT-5' (APP4anti)

E. TARGET: UNKNOWN

DNA Duplex Target

-286 -252

5' -CTCACCTTCCCTGATCCTGCACCGTCCCTCCT-3
 3' -GAGTGGAAAGGGACTAGGACGTGGCAGGGAGAGGA-5

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GTGTGGTTGGGTGTTGGTGGTGGGTGGGTGTTG-5' (APP5par)
30 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GTGTGGTTGGGTGTTGGTGGTGGGTGGGTGTTG-3' (APP5anti)

E. TARGET: UNKNOWN

35 DNA Duplex Target

-264 -230

40 5' -CCGTCCCTCTCCTGGCCCCAGACTCTCCCTCCC-3'
3' -GGCAGGGAGAGGACCGGGGTCTGAGAGGGAGGG-5'

45 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGGTGGGTGTGGTGGGGGGTGTGTGTTGGG-5' (APP6par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGGTGGGTGTGGTGGGGGGTGTGTGTTGGG-3' (APP6anti)

G. TARGET: UNKNOWN

50 DNA Duplex Target

-200 -177

55 5' -GGGGAGCGGAGGGGGCGCGTGGGG-3
 3' -CCCTCGCCTCCCCCGCGCACCCC-5'

EP 0 375 408 B1

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGGGTGGGGTGGGGGGGGTGGGG-3' (APP7par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGGGTGGGGTGGGGGGGGTGGGG-5' (App7anti)

H. TARGET: UNKNOWN

DNA Duplex Target

10 -40 -9
 5' -CTCGCCTGGCTCTGAGCCCCGCCCGGCTC-3'
 3' -GAGCGGACCGAGACTCGGGGCGGCAGCAG-5'

15 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GTGGGGTGGGTGTGTTGGGGGGGGGGGGGGTG-5' (APP8par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GTGGGGTGGGTGTGTTGGGGGGGGGGGGGGTG-3' (APP8anti)

20

Example 7

THE EGFR PROMOTOR DOMAIN

Inappropriately high expression of the epidermal growth factor gene (EGFR) has been implicated as crucial to the development of cancers and several skin diseases (psoriasis). The synthetic oligonucleotides described below were designed to selectively repress the expression of the EGFR gene in such diseases.

A. TARGET: SP1 BINDING SITE

30 DNA Duplex Target

-109 -83

35 5' -TCCGCCGAGTCCCCGCCCTGCCGCC-3'
 3' -AGGCCTCGAGGGGGGGAGCGGGGG-5'

40 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TGGGGGGTGTGGGGGGTGGGGGG-5' (EGFR1par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TGGGGGGTGTGGGGGGTGGGGGG-3' (EGFR1anti)

B. TARGET SP1 BINDING SITE

45 DNA Duplex Target

-307 -281

50 5' -TCCCTCCTCCTCCCCGCCCCCTGCCTCCCC-3'
 3' -AGGGAGGGAGGGAGGGCGGGACGGAGGG-5'

55 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TGGGTGGTGGTGGGGGGGGGGTGGG-5' (EGFR2par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TGGGTGGTGGTGGGGGGGGGGTGGG-3' (EGFR2anti)

EP 0 375 408 B1

C. TARGET: SP1 BINDING SITE

DNA Duplex Target

5 **-352** **-317**
5 ' -TTCTCCTCCCTCTGCTCTCCCGATCCCTCCTCC-3 '
3 ' -AAGAGGAGGAGGAGACGAGGAGGGCTAGGGAGGAGG-5 '

10 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TTGTGGTGGTGGTGGTGGTGGGGTGGTGG-5' (EGFR3par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTGTGGTGGTGGTGGTGGTGGGGTGGTGG-3' (EGFR3anti)

15 D. TARGET: NUCLEASE SENSITIVE DOMAIN REQUIRED FOR EGFR EXPRESSION

DNA Duplex Target

20 **-363** **-338**
5 ' -TTCTCCTCCCTCTCCTCGCATTCTCCTCCTCT-3 '
3 ' -AAGAGGAGGGAGGAGGAGCGTAAGAGGAGGAGGAGA-5 '

25 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TTGTGGTGGGTGGTGGTGGGTGGGTGGTGGTGGT-5' (EGFR4par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTGTGGTGGGTGGTGGTGGGTGGGTGGTGGTGGT-3' (EGFR4anti)

30 Example 8

THE GSTpi GENE

35 Overexpression of the enzyme glutathione-s-transferase pi has been implicated as being responsible for the broad-range drug resistance which develops in a variety of cancers. The synthetic oligonucleotides described below are designed to repress GST-pi expression, thereby sensitizing cancerous tissue to traditional drug chemotherapy.

40 A. TARGET SITE: The target-domain comprises the consensus binding sequences for the transcription activating factors AP1 & Sp1. Synthetic Oligonucleotides targeted against this will repress GSTpi transcription by means of competition with AP1 and Sp1.

DNA Duplex Target

45 **-68** **-39**
5 ' -GACTCAGCACTGGGGCGGAGCGGGGGCGGGA-3 '
50 3 ' -CTGAGTCGTGACCCCGCCTCGCCCCGCCCT-5 '

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GTGTGTGGTGTGGGGGGGGTGGGGGGGGGGT-3' (GST1par)
55 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GTGTGTGGTGTGGGGGGGGTGGGGGGGGGGT-5' (GST1anti)

EP 0 375 408 B1

B. TARGET SITE: An enhancer-like polypurine sequence. A synthetic oligonucleotide targeted against this site will repress GSTpi transcription by means of competition with the enhancer.

5 -227 -204
5' -GGGGACCTGGGAAAGAGGGAAAGG-3'
3' -CCCTGGACCCTTCTCCCTTCC-5'

10 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGGGTGGTGGGTTGTGGGTTGG-3' (GST2par)
15 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGGGTGGTGGGTTGTGGGTTGG-5' (GST2anti)

An unusual repetitive DNA segment. No function has been ascribed to this segment yet. However, it is within the control domain and may play a role in transcription initiation.

DNA Duplex Target

20 -499 -410
5'-AAAATAAAATAAAATAAAATAAAATAAAAT-3'
3'-TTTATTATTATTATTATTATTATTATTTA-5'

25 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTTTTTTTTTTTTTTTTTTTTTTTTT-3' (GST3par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
30 3'-TTTTTTTTTTTTTTTTTTTTTTTT-5' (GST3anti)

Example 9

The HMGCoA REDUCTASE GENE

35 HMGCoA Reductase is the enzyme which defines the rate limiting step in cholesterol biosynthesis. Its molecular genetics has been studied to understand the control of cholesterol synthesis. The described synthetic oligonucleotides will intervene in the program of cholesterol synthesis by means of modulating the transcription of HMGCoA.

40 A. TARGET SITE: The target is the binding site for a repressor protein that appears to mediate end-product inhibition of transcription by cholesterol. The synthetic oligonucleotide is a synthetic repressor of HMGCoA expression, as an agonist of the cellular repressor.

45 DNA Duplex Target

-167 -135

5' -GGTGAGAGATGGTGC^GGTGCCGTTCTCCGCC-3'

3' -CCACTCTCTACCACGCCACGGCAAGAGGGCGGG-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGTGTGTTGGTGGGGTGGGGGG-5' (HMGCOA1par)
55 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGTGTGTTGGTGGGGTGGGGGG-3' (HMGCOA1anti)

EP 0 375 408 B1

B. TARGET SITE: The target is a binding site for protein that appears to activate transcription of HMGCoA. The synthetic oligonucleotide against this site is a synthetic repressor of HMGCoA expression, as an antagonist of the cellular protein which binds to the target.

5 DNA Duplex Target

-134 -104

5' -GGGTGCGAGCAGTGGGCCGTTGTTAAGGCAG-3'
 10 3' -CCACAGCTCGTCACCCGCCAACAAATTCCGCT-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGGTGGGTGGTGGGGGGGTTGGGGT-3' (HMGCOA2par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

3'-GGGTGGGTGGTGTGGGGGGTTGTTTGGGGT-5' (HMGCOA2anti)

C. TARGET SITE: The target is a binding site for a protein that appears to activate transcription of HMGCoA by binding to the "TATA box" domain. A TFO against this site is designed to be a synthetic repressor of HMGCoA expression, as an antagonist of the cellular protein which binds to the TATA box target.

DNA Duplex Target

25 -41 -6
5'-AGGCGATCGGACGATCCTTCTTATTGGCGGCCCT-3'
3'-TCCGCTAGCCTGCTAGGAAAGAATAACCGCCGGGA-5'

30 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TGGGGTTGGGTGGTTGGTTGTTTGGGGGGGGT-5' (HMGCOA3par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE

35

Name: S. A. Raman (INGER)

40 The NGFR gene encodes a cell surface receptor required for nerve cell proliferation. It is overexpressed in neuroblastoma and melanomas. Triplex oligonucleotides are designed to repress the growth of those cancerous tissues. Activation of the gene would be a precondition of activation of nerve cell regeneration. The mRNA start site is at -122 in this number scheme.

15 A TARGET SITE: Consensus Sp1 binding site

DNA Duplex Target

50 -323 -290
 5' -GGGAACTGGGTACCAAGGGCGGGATGGGTGAGAGGG-3'
 3' -CCCTTGACCCATGGTCCCCCCTACCCACTCTCC-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGGTTGTGGGTTGGTGGGGGGGGTGGGTGIGTGG-3' (NGFR1par)

EP 0 375 408 B1

**ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGGTTGTGGGTTGGTGGGGGGGGTGGGTGTGTGG-5' NGFR1ap**

B. TARGET SITE. Consensus SP1 binding site.

5

DNA Duplex Target

15 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGGGGGGGTTGGGTGTGTTGGTGGTGGTGG-3' (NGFR2par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGGGGGGGTTGGGTGTGTTGGTGGTGG-5' (NGFR2anti)

C. TARGET SITE: Domain flanking consensus Sp1 binding sites

DNA Duplex Target

25 -285 -248
 5' -AAGGGACAAGGCAGGGAGAACCGCACGGGTGCGGGAA-3'
 30 3' -TTCCCTGTTCCGTCCCTCTTCGCGTGCCACGCCCTT-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTGGGTGTTGGGTGGGTGTTGGGTGGGGTGGGGT-3' (NGFR3par)
35 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TTGGGTGTTGGGTGGGTGTTGGGTGGGGTGGGGT-5' (NGFR3anti)

D. TARGET SITE: Domain flanking consensus Sp1 binding sites.

30 DNA Duplex Target

-243 -216
 5' -CCCTCCCTTGCCTCTGCTTCCCACCCC-3'
 45
 3' -GGGAGGGAAACGGAGACGAAGGGTGGGG-5'

50 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
 5'-GGGTGGGTTGGTGTGGTTGGG-3' (NGFR4par)
 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
 3'-GGGTGGGTTGGTGTGGTTGGG-5' (NGFR4anti)
 TARGET SITE: Consensus Sp1 binding site.

55 DNA Duplex Target

-187 -154
5' -GGGGGTGGGCGGGCTGGCGGGGGCGAGGCAGGGGG-3'

5 3' -CCCCCACCCGCCCGACCGCCCCGCCTCCGCCCCC-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
10 5'-GGGGGTGGGGGGGGTGGGGGGGGTGGGGGGGG-3' (NGFR5par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGGGGTGGGGGGGTGGGGGGGGTGGGGGGGG-5' (NGFR5anti)

Example 11

15 HERPES SIMPLEX VIRUS 1: DNA Polymerase and DNA binding proteins

HSV-1 is responsible for a variety of skin lesions and other infections. The triplex oligonucleotide are designed to bind directly to the promoter region of the genes which encode the viral DNA polymerase and
20 DNA binding protein, thereby arresting viral replication. Both genes occur at 0.4 map units and flank the replication origin oriL. Numbering below is in terms of the polypeptide start site for each gene.

A. TARGET SITE This site is in the 5' flanking sequence of the DNA polymerase gene. The Angelotti strain has three base changes relative to strain 17.

25 (1) Strain 17

DNA Duplex Target

30 -60 -26
5' -TTTTCTCTCCCCCTCCCCACATCCCCCTCTT-3'

35 3' -AAAAAGAGAAGGGGGGAGGGGTGTAAGGGGAGAAA-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TTTTGTGTTGGGGGGTGGGGTGTGGGGGTGTT-5' (HSVPO17par)
40 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTTTGTGTTGGGGGGTGGGGTGTGGGGGTGTT-3' (HSVPO17anti)

(2) Strain Angelotti

45 -62 -26
5' -TTTTCTCTCCCCCTCCCCACATCCCCCTCTT-3'

50 3' -AAAAAGAGAAGGGGGGAGGGGTGAGGGGGGAGAAA-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
55 3'-TTTTGTGTTGGGGGGTGGGGTGTGGGGGTGTT-5' (HSVPO1par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTTTGTGTTGGGGGGTGGGGTGTGGGGGTGTT-3' (HSVPO1anti)

EP 0 375 408 B1

A. TARGET SITE: This site is in the 5' flanking sequence of the DNA binding protein gene for strain 17.

5' -AAAATCCGGGGGGGGCGCGACGGTCAAGGGGAGGG-3'

3' - TTTAGGCCCCCCCCCGCCGCTGCCAGTTCCCCCTCCC-5'

10

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTTTGGGGGGGGGGGGGGGGGGTGGGTGGTGGGGTGGG-3' (HSVPOL2par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TTTTGGGGGGGGGGGGGGGGGGTGGGTGGTGGGGTGGG-5' (HSVPOL2anti)

Example 12

HERPES SIMPLEX VIRUS 1: origin of replication

20 HSV-1 is responsible for a variety of skin lesions and other infections. The triplex oligonucleotides are
designed to bind directly to the two classes of HSV-1 DNA replication origin, thereby arresting viral
replication. The first origin (oriL) occurs at 0.4 map units and is in between and immediately adjacent to the
HSV-1 DNA polymerase and DNA binding protein genes. The two identical origins of the second type (oriS)
25 occur at 0.82 and 0.97 map units. Numbering below is the terms of position relative to the two fold
symmetry axis of each origin.

A. TARGET SITE oriL origin

30 1. DNA Duplex Target

-48 -10

35 5' -AGGACAAAGTGCACGCTTCGCGTTCTCACTTTTTT-3'

3' -TTTTTTTCACTCTTGCCTTCGCAAGCGTGAAACAGGA-5'

40 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTTTTTTGTTGTTGGGGTTGGGTGGGTGGT-3' (HSVORL1par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TTTTTTGTTGTTGGGGTTGGGTGGGTGGT-5' (HSVORL1anti)

50

55

EP 0 375 408 B1

2. DNA Duplex Target

5 10 47
5'-AGGACAAAGTGC^ACGCTTCGCGTTCTCACTTTTTT-3'

3' -TCCTCTTCTCGCTTGCAGCGCAAGAGTGAAAAAAA-5'

**PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TGGTGTGTTGGGTTGGGTTGGGTTGTTGTTT-5' (HSVORL2par)**

These two target sites are within the oriL origin. Because the oriL also comprises the 5' flanking domain of the HSV-1DNA polymerase and the HSV-1 major DNA binding protein, these triplex oligonucleotides may also interfere with transcription of those two genes.

20

B. TARGET SITE: oriS organ

-69 -34
5'-AAGGGGGCGGGGCCGCCGGTAAAAGAAGTGAGAA-3'

3'-TTCCCCCGCCCCGGCGGCCATTTCTTCACTCTT-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTGGGGGGGGGGGGGGGGGGGGGGGTTTTGTGGTGTGTT-3' (HSVORS1par)
35 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TTGGGGGGGGGGGGGGGGGGGGGGGTTTTGTGGTGTGTT-5' (HSVORS1anti)

Example 13

40 HUMAN BETA GLOBIN

The beta globin gene encodes one of the proteins comprising adult hemoglobin. Mutation in this gene is responsible for beta thalassemia and sickle cell anemia. Triplex oligonucleotides targeted to this gene are designed to inhibit the beta globin gene in thalassemics and in patients with sickle cell anemia, to be replaced by the naturally occurring delta protein. Two classes of triplex oligonucleotides TFO are described, which are targeted against the 5' enhancer or the promotor/coding domain. Numbering is relative to the principal mRNA start site.

50

55

EP 0 375 408 B1

A. DNA Duplex Target

5 -912 -886
5'-CCTTTCCCCCTCCCTACCCCTACTTTCT-3'

3' -GGAAAAGGGGAGGATGGGGATGAAAGA-5'

10

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGTTTGGGTGGTTGGGTT-5' (GL1par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGTTTGGGTGGTTGGGTT-3' (GL1anti)

B. DNA Duplex Target

20 -63 -25
5'-AGGAGCAGGGAGGGCAGGAGCCAGGGCTGGGCATAAAAG-3'

3' -TCCTCGTCCCTCCCGTCCTCGGTCCCCACCCGTATTTTC-5'

PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TGGTGGTGGGTGGGGTGGTGGGTGGGGTGGGGTTTTTG-3' (GL2par)
30 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE)
3'-TGGTGGTGGGTGGGGTGGTGGGTGGGGTGGGGTTTTTG-5' (GL2anti)

C. DNA Duplex Target

35 -36 -9
51 AGCGCTGGGNTNNAGTCGACCGAGTC

24. [Помощь в создании сайта](#) | [Создание сайтов](#)

45 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
 5'-GGGGTGGGGTTTTTGTTGTTGGGTGTG-3' (GL3par)
 ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
 3'-GGGGTGGGGTTTTTGTTGTTGGGTGTG-5' (GL3anti)

50

55

EP 0 375 408 B1

D. DNA Duplex Target

5 514 543
5 ' -CCCTTGATGTTTCTTCCTCCCTTCTTCT-3 '

10 3 ' -GGGAACATACAAAGAAAGGGGAAGAAAAGA-5 '

15 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GGGTTGTTGTTGTTGGGTTGTTGT-5' (GL4par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GGGTTGTTGTTGTTGGGTTGTTGT-3' (GL4anti)

E. DNA Duplex Target

20 693 719

5 ' -TTCTTGCTTCCTTTTTCTCTCC-3 '

25 3 ' -AAGAACGAAAGAAAAAAAAGAAGAGG-5 '

30 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-TTGTTGGTTGTTTTTTGTTGTGG-5' (GL5par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-TTGTTGGTTGTTTTTTGTTGTGG-3' (GL5anti)

35 F. DNA Duplex Target

40 874 900

5 ' -CTCCCTACTTATTTCTTTATTTT-3 '

45 3 ' -GAGGGATGAAATAAAAGAAAATAAAA-5 '

45 PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
3'-GTGGGTTGTTTTTTGTTTTTTT-5' (GL6par)
ANTI-PARALLEL SYNTHETIC OLIGONUCLEOTIDE SEQUENCE
5'-GTGGGTTGTTTTTTGTTTTTTT-3' (GL6anti)

50 Example 14

Testing for the effect of oligonucleotide binding in cells. The effects of triplex-forming oligonucleotides are studied in cell culture. Oligonucleotides are administered to cultured human cell lines, which are then analyzed for oligonucleotide uptake and for a change in the steady-state level of messenger RNA associated with the DNA target. As an example, the methods for the c-myc gene are shown. One skilled in the art will readily be able to generalize to any gene within a cultured cell.

HeLa cells grown on a solid support (100ul total volume), are treated with ^{32}P -labelled oligonucleotide, then incubated as a function of time and concentration. Cells are separated from serum by centrifugation and exhaustive washing, are disrupted by deproteinization then assayed quantitatively on a 8% sequencing gel. This analysis procedure yields the following characteristics:

- 5 a. The apparent partition coefficient for oligonucleotide uptake into HeLa cells.
- b. The uptake rate, i.e., the time constant to reach a steady state with respect to oligonucleotide uptake.
- c. The half-time for oligonucleotide degradation in serum and in the HeLa cell.

From those data, the optimized timecourse and titration range for the oligonucleotide treatment of cells is determined.

10 Transcription inhibition is assayed by a variation of the RNase protection assay, which is the standard assay for quantifying steady state mRNA levels in mammalian cells. Total cellular RNA is extracted from oligonucleotide-treated HeLa cells, then hybridized to a uniformly labelled antisense RNA transcript, generated by the action of T7 polymerase on the Smal-Pvull human c-myc fragment in pSPT19.

This Smal-Pvull probe is complementary to the first myc exon and sequences which comprise both the 15 P1 and P2 transcription start sites of myc. When the probe is hybridized in excess over myc transcript, a limit RNase digest produces either a 0.6 kb duplex (transcription from P1, which is the preferred origin in HeLa cells) or a 0.4 kb duplex (transcription occurs instead from P2, which is used in HeLa cells under conditions of serum starvation).

The size and quantity of the resulting RNase resistant duplexes is then determined by quantitative 20 autoradiography on a 5% acrylamide gel matrix. This assay system can quantify steady-state RNA levels to within 20% accuracy, which is sufficient for the purposes of this analysis.

The outcome of these cellular titrations is analyzed in the context of two control experiments. The first 25 is a comparison of the dose response of oligonucleotides which bind selectively to the target gene and the dose response of oligonucleotides which are unrelated. If oligonucleotide-mediated repression of the c-myc transcription is due to site-specific triplex formation in the cell, then an unrelated oligonucleotide will not elicit an effect, over an equivalent concentration range.

The second control addresses the gene specificity of the effect. In the RNase protection assay, data are 30 always normalized to overall RNA concentration in the cell. As such, changes in the steady state level of the myc transcript are meaningful in their own right. However to confirm that the effects of oligonucleotide binding are specific to the c-myc gene we also assay for the effect of myc-specific oligonucleotide treatment on the steady state levels of the histone 2A (H2A) message in HeLa cells, probing the RNA complement with an H2A antisense RNA, generated from a construct which, as for myc sequences, has been cloned into a RNA expression vector. When oligonucleotide mediated repression is specific to the myc gene, H2A transcription in HeLa cells will be unaffected, over an equivalent concentration range.

35 Over the 1 to 50 micro-molar range, oligonucleotides which bind to the control region of the human c-myc gene selectively repress c-myc transcription in an intact HeLa cell. Preliminary work with other oligonucleotides described in the examples have begun to display similar selectivity.

One skilled in the art will recognize that application of these methods is readily generalized to any gene 40 in any cell line and is limited only by the availability of cloned gene constructs, DNA sequence data, and a rudimentary understanding of the molecular genetics of the gene under investigation. At present, that battery of information is available for several hundred human genes, and for several thousand genes from other species.

The methods can also be applied, without significant modification to the use of chemically altered 45 oligonucleotides variants, such as those with chemical moieties added to the 3'and 5' terminus, oligonucleotides with an altered phosphodiester backbone or those with bases other than G and T (i.e., iodo-G or X).

Ultimately, the importance of these examples is to show that a whole class of single strand 50 oligonucleotide molecules are readily taken up by eukaryotic cells, without exogenous manipulation of any kind. The uptake mechanism is not known at present, but in host cells, it is efficient and, apparently, independent of oligonucleotide sequence (Eppstein D.A., Schryver B.B. & Marsh Y.V. (1986) J. Biol.Chem. 261, 5999). Therefore, in the most general sense, the overall uptake properties of such oligonucleotides are not significantly different from other potent drugs. By this criterion, it is certain that an oligonucleotide ligand designed to selectively intervene into the process of gene expression will show pharmacological effects in an intact cell.

55 In the past, these cell uptake concepts have been used to explain the effectiveness of RNA oligonucleotides as drugs which enhance the effect of interferon treatment (Eppstein D.A., Schryver B.B. & Marsh Y.V. (1986) J. Biol.Chem. 261, 5999) and of the ability of "antisense" or "anti-splice junction" oligonucleotides to selectively inhibit mRNA processing in the cell (Heikkila R. et. al. (1987) Nature 328, 445

and Eppstein D.A., Schryver B.B. & Marsh Y.V. (1986) J. Biol. Chem. 261, 5999. It is likely that the same uptake process is the basis for the use of triplex-forming oligonucleotides as drugs to selectively regulate transcription initiation or to selectively destroy a gene target.

The design process described herein can be used to design a synthetic DNA oligonucleotide which will bind specifically to any double strand DNA target of interest. The resulting oligonucleotide-duplex DNA complex is best described as a colinear triplex. In the triplex the oligonucleotide molecule occupies the major groove of the duplex. The complex is stabilized by base-base hydrogen bonding at the surface of the major groove, leaving Watson-Crick pairing intact. As a result, the stability and site specificity of the synthetic oligonucleotide is not significantly affected by modification of the phosphodiester linkage or by chemical modification of the oligonucleotide terminus. Consequently, these oligonucleotides can be chemically modified; enhancing the overall binding stability, increasing the stability with respect to chemical degradation, increasing the rate at which the oligonucleotides are transported into cells, and conferring chemical reactivity to the molecules.

Based upon the design method described herein, it is possible to design oligonucleotides which are readily taken up by eukaryotic cells and, once in the cell, can be targeted to specific sites within a genome. Currently, the site specificity and stability of the synthetic oligonucleotide-target site interaction is as good as current monoclonal antibody-antigen binding interactions.

This new class of site specific molecules can be used as gene-specific reagents with the capacity to control the transcription process in a gene-specific fashion. This control is effective on both somatic genes and viral genes which have infected a host cell. When synthetic oligonucleotides are appropriately coupled to a reactive chemical complement, it is possible to create a hybrid molecule with the capacity to selectively destroy a gene target of interest.

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and attain the ends and advantages mentioned as well as those inherent therein. The oligonucleotides, compounds, methods, procedures and techniques described herein are presently representative of preferred embodiments, are intended to be exemplary, and are not intended as limitations on the scope.

Claims

1. A method for making a synthetic oligonucleotide which binds to a target sequence in duplex DNA forming a collinear triplex by binding to the major groove, the method comprising the steps of:
 - identifying from within genomic duplex DNA a nucleotide target sequence of greater than about 20 nucleotides having either about at least 65% purine bases or about at least 65% pyrimidine bases; and
 - synthesizing the synthetic oligonucleotide complementary to the identified target sequence, the synthetic oligonucleotide having a G when the complementary location in the DNA duplex has a GC base pair, and having a T when the complementary location in the DNA duplex has an AT base pair.
2. A method according to Claim 1, wherein at least one T of the oligonucleotide is replaced with a compound selected from X, halogenated derivatives of X, I and halogenated derivatives of I.
3. A method according to Claim 1 or Claim 2, wherein at least one G of the oligonucleotide is replaced with a halogenated derivative of G.
4. A method according to any one of the preceding claims, wherein at least one base of the oligonucleotide is substituted at the 2' furanose position with a non-charged bulky group.
5. A method according to Claim 4, wherein the non-charged bulky group is selected from a branched alkyl, a sugar and a branched sugar.
6. A method according to any one of the preceding claims, wherein the backbone of the oligonucleotide is a phosphodiester analogue which is not readily hydrolyzed by cellular nucleases.
7. A method according to Claim 6, wherein the phosphodiester analogue is selected from phosphorothioate, phosphoroselenoate, methyl phosphate, phosphoramidite, phosphotriester and the alpha enantiomer of naturally occurring phosphodiester.

8. A method according to any one of the preceding claims, further including a linker at a terminus of the oligonucleotide.
9. A method according to Claim 8, wherein the oligonucleotide further includes a modifying group attached to the linker, wherein the modifying group binds to duplex DNA and is selected from an intercalator, a groove-binding molecule, a cationic amine and a cationic polypeptide.
10. A method according to Claim 8, wherein the oligonucleotide further includes a modifying group attached to the linker, wherein the modifying group damages DNA and is selected from a catalytic oxidant, a nitrogen mustard, an alkylator, a photochemical crosslinker, a photochemical sensitizer of singlet oxygen and a reagent capable of direct photochemical damage.
11. A method according to Claim 10, wherein the photochemical sensitizer of singlet oxygen is eosin, methylene blue, acridine orange, or 9 amino acridine.
12. A method according to Claim 11, wherein the reagent is ethidium or a pyrene derivative.
13. A method according to claim 10, wherein the modifying group is selected from an eosin isothiocyanate, a psoralin derivative and a metal chelate.
14. A synthetic oligonucleotide intended and adapted to bind to an identified target sequence in duplex DNA to form a collinear triplex when the target sequence is either about at least 65% purine bases or about at least 65% pyrimidine bases, comprising:
 - a nucleotide sequence containing from about 20 to 40 nucleotides;
 - the nucleotide sequence including G and T, wherein G is present when the complementary location in the duplex DNA is a GC base pair and T is present when the complementary location in the duplex DNA is an AT base pair; and
 - the sequence being selected from an oligonucleotide orientated 3' to 5' and binding anti-parallel to the about at least 65% purine strand in the duplex DNA target sequence and an oligonucleotide orientated 5' to 3' and binding parallel to the about at least 65% purine strand in the duplex DNA target sequence.
15. A synthetic oligonucleotide according to claim 14, wherein the nucleotide sequence is of equal oligonucleotide length to the target sequence.
16. A synthetic oligonucleotide according to claim 14 or claim 15 having a dissociation constant of from 6×10^{-10} to 1.5×10^{-7} molar.
17. A synthetic oligonucleotide according to claim 16 having a dissociation constant of from about 10^{-9} to 10^{-8} molar.
18. A synthetic oligonucleotide according to Claim 14, wherein at least one T is replaced with a compound selected from X, halogenated derivatives of X, I and halogenated derivatives of I.
19. A synthetic oligonucleotide according to Claim 14, wherein at least one G is replaced with a halogenated derivative of G.
20. A synthetic oligonucleotide according to Claim 14, wherein at least one base is substituted at the 2' furanose position with a non-charged bulky group.
21. A synthetic oligonucleotide according to Claim 20, wherein the non-charged bulky group is selected from a branched alkyl, a sugar and a branched sugar.
22. A synthetic oligonucleotide according to Claim 14, wherein the backbone is a phosphodiester analogue which is not readily hydrolyzed by cellular nucleases.
23. A synthetic oligonucleotide according to Claim 22, wherein the phosphodiester analogue is selected from phosphorothioate, phosphoroselenoate, methyl phosphate, phosphoramidite, phosphotriester and

the alpha enantiomer of naturally occurring phosphodiester.

24. A synthetic oligonucleotide according to Claim 14, further including a linker at a terminus.
- 5 25. A synthetic oligonucleotide according to Claim 24, wherein the linker is attached to the 3' terminus and is selected from a base analogue with a primary amine affixed to the base plane through an alkyl linkage and a base analogue with a sulphydryl affixed to the base plane through an alkyl linkage.
- 10 26. A synthetic oligonucleotide according to Claim 24, wherein the linker is attached to the 5' terminus and is selected from a base analogue with a primary amine affixed to the base plane through an alkyl linkage, a base analogue with a sulphydryl affixed to the base plane through an alkyl linkage, a long chain amine coupled directly to the 5' hydroxyl group of the oligonucleotide and a long chain thiol coupled directly to the 5' hydroxyl group of the oligonucleotide.
- 15 27. A synthetic oligonucleotide according to any one of Claims 24, 25 or 26, further including a modifying group attached to the linker, wherein the modifying group binds to duplex DNA and is selected from an intercalator, a groove-binding molecule, a cationic amine and a cationic polypeptide.
- 20 28. A synthetic oligonucleotide according to any one of Claims 24, 25 or 26, further including a modifying group attached to the linker, wherein the modifying group damages DNA and is selected from a catalytic oxidant, a nitrogen mustard, an alkylator, a photochemical crosslinker, a photochemical sensitizer of singlet oxygen and a reagent capable of direct photochemical damage.
- 25 29. A synthetic oligonucleotide according to Claim 28, wherein the photochemical sensitizer of singlet oxygen is eosin, methylene blue, acridine orange, or 9 amino acridine.
- 30 30. A synthetic oligonucleotide according to Claim 28, wherein the reagent is ethidium or a pyrene derivative.
- 35 31. A synthetic oligonucleotide according to claim 28, wherein the modifying group is selected from an eosin isothiocyanate, a psoralin derivative and a metal chelate.
32. A synthetic oligonucleotide according to Claim 14 for administering in sufficient amount for cellular uptake and binding to the target sequence to inhibit the growth of cells, wherein the target sequence is positioned within the DNA domain adjacent to the RNA transcription origin.
- 35 33. A synthetic oligonucleotide according to Claim 32, wherein the cells are cancerous cells and the synthetic oligonucleotide is specific to the C-myc gene.
- 40 34. A synthetic oligonucleotide according to Claim 33, wherein the synthetic oligonucleotide is selected from:
 - 3'-TGGGTGTTGGGTTTGTGGGGGGGTGGGGGGGGTTTTTTGGGTGGG-5',
 - 5'-TGGGTGTTGGGTTTGTGGGGGGGTGGGGGGGGTTTTTTGGGTGGG-3',
 - 5'-GTGGTGGGGTGGTTGGGGTGGGTGGGGTGGGTGGGTGGGTGGG-3',
 - 45 3'-GTGGTGGGGTGGTTGGGGTGGGTGGGTGGGTGGGTGGGTGGG-5',
 - 3'-GGTTGGGGTGGGTGGGGTGGGTGGGTGGGTGGGTGGG-5',
 - 5'-GGTTGGGGTGGGTGGGGTGGGTGGGTGGG-3',
 - 3'-TTGGGTGTTGGGGGTGGGGGTGGGTGGGTGGGTGGGTGGG-5' and
 - 5'-TTGGGTGTTGGGGGTGGGGGTGGGTGGGTGGGTGGG-3'.
- 50 35. A synthetic oligonucleotide according to Claim 34, wherein the oligonucleotide includes a linker and modifying group.
- 55 36. A synthetic oligonucleotide according to Claim 14 for administering in sufficient amount for cellular uptake and binding to the target sequence to inhibit the growth of pathogens, wherein the sequence binds within the nucleic acid domain adjacent the RNA transcription origin.

	3'-TTTTGTTTGTCTTCCTTCTTT-5', 3'-TGGTGGGGGTTGGTGGTTGGTTGT-5', 5'-TGGTGGGGGTTGGTGGTTGGTTGT-3', 3'-TTGTGTTGTGTTGGTGTGGGGTGGGTGGTGG-5', 5'-TTGTGTTGTGTTGGTGTGGGGTGGGTGGTGGTGG-3', 5'-GTGTGTTTGGTTGGTTGGGGTTTTT-3', 3'-GTGTGTTTGGTTGGTTGGGGTTTTT-5', 3'-GTGTGTTGGGTGGTGGTGGTGGGTTGGTGGT-5', 5'-GTGGTGGTTGGGTGGTGGTGGTGGGGTGGTGGT-3', 3'-GGGTGGGTGTGGTGGGGGGGTGTGTGTGGGTGGG-5', 5'-GGGTGGGTGTGGTGGGGGGGTGTGTGTGGGTGGG-3', 5'-GGGGTGGGGTGGGGGGGGGGTGGGG-3', 3'-GGGGTGGGGTGGGGGGGGGGTGGGG-5', 3'-GTGGGGTGGGTGTGTGGGGGGGGGGGTG-5' and 5'-GTGGGGTGGGTGTGTGGGGGGGGGGGGTGTG-3'.
5	
10	
15	

50. A synthetic oligonucleotide according to Claim 14 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to repress the expression of the epidermal growth factor gene.

20

51. A synthetic oligonucleotide according to Claim 50 for repressing expression of the epidermal growth factor gene, wherein the synthetic oligonucleotide is selected from:

3'-TGGTGGGGGTTGGTGGTTGGTGGTGTG-5',
5'-TGGTGGGGGTTGGTGGTTGGTGGTGTG-3',
3'-TGGGTGGTGGTGGGGGGTGGGTGGG-5',
5'-TGGGTGGTGGTGGTGGTGGTGGGGTGGG-3',
3'-TTGTGGTGGTGGTGTGGTGGTGGGGTGGGTGGG-5',
5'-TTGTGGTGGTGGTGTGGTGGTGGGGTGGGTGGG-3',
3'-TTGTGGTGGGTGGTGGTGGGTGGTGGTGGTGTG-5' and
30 5'-TTGTGGTGGGTGGTGGTGGGTGGTGGTGTG-3'.

52. A synthetic oligonucleotide according to Claim 14 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to repress the glutathione-s-transferase pi gene.

35

53. A synthetic oligonucleotide according to Claim 52 for repressing the glutathione-s-transferase pi gene, wherein the synthetic oligonucleotide is selected from:

5'-GTGTGTGGTGTGGGGGGGTGGGGGGGGGT-3',
3'-GTGTGTGGTGTGGGGGGGTGGGGGGGGGT-5',
5'-GGGGTGGTGGGTTTGTTGGGTTTG-3',
3'-GGGGTGGTGGGTTTGTTGGGTTTG-5',
5'-TTTTTTTTTTTTTTTTTTTTTTTTTTTT-3' and
40 3'-TTTTTTTTTTTTTTTTTTTTTTTTTT-5'.

54. A synthetic oligonucleotide according to Claim 14 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to intervene in the programme of cholesterol synthesis by modulating the transcription of the enzyme which defines the rate limiting step in cholesterol biosynthesis known as HMGCoA reductase.

45

55. A synthetic oligonucleotide according to Claim 54 for modulating the transcription of the enzyme which defines the rate limiting step in cholesterol biosynthesis known as HMGCoA reductase, wherein the synthetic oligonucleotide is selected from:

3'-GGGTGTGGTGGTGGGGTGGGGGGTGGGGGG-5',
5'-GGGTGTGGTGGTGGGGTGGGGGGTGGGGGG-3',
5'-GGGTGGGTGGTGTGGGGGGTGGGGGG-3',
3'-GGGTGGGTGGTGTGGGGGGTGGGGGG-5',
3'-TGGGGTGGGTGGTGGTGGGGGGTGGGGGG-5' and
5'-TGGGGTGGGTGGTGGTGGGGGGTGGGGGG-3'.

63. A colinear triplex according to claim 62, wherein the oligonucleotide length of the target sequence is equal to that of the synthetic oligonucleotide.
64. A synthetic oligonucleotide obtainable by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence to inhibit the growth of cells, wherein the target sequence is positioned within the DNA domain adjacent to the RNA transcription origin.
5
65. A synthetic oligonucleotide obtainable by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence to inhibit the growth of pathogens, wherein the sequence binds within the nucleic acid domain adjacent the RNA transcription origin.
10
66. A synthetic oligonucleotide obtainable by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to manipulate the structural protein content of epidermal tissue.
15
67. A synthetic oligonucleotide obtainable by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to permanently inhibit gene expression.
20
68. A synthetic oligonucleotide obtainable by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to alter the characteristics of muscle proteins in food animals.
25
69. A synthetic oligonucleotide made by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to inhibit the interleukin 2 alpha chain receptor.
70. A synthetic oligonucleotide made by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to disperse plaque formation in Alzheimer's Disease.
30
71. A synthetic oligonucleotide made by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to repress the expression of the epidermal growth factor gene.
35
72. A synthetic oligonucleotide made by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to repress the glutathione-s-transferase pi gene.
40
73. A synthetic oligonucleotide made by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to intervene in the programme of cholesterol synthesis by modulating the transcription of the enzyme which defines the rate limiting step in cholesterol biosynthesis known as HMGCoA reductase.
45
74. A synthetic oligonucleotide made by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to suppress expression of the nerve growth factor receptor.
50
75. A synthetic oligonucleotide made by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake and binding to the target sequence so as to arrest viral replication of the Herpes Simplex Virus 1.
76. A synthetic oligonucleotide made by a method according to any one of Claims 1 to 13 for administering in sufficient amount for cellular uptake binding to the target sequence so as to suppress beta globin gene synthesis in thalassemics and sickle cell anaemics.
55

Patentansprüche

1. Verfahren zur Herstellung synthetischer Oligonukleotide, die an Bestimmungstellen auf Duplex-DNA-Molekülen binden, durch Formen eines kollinearen Triplex durch Bindung mit der Haupt-Vertiefung, gekennzeichnet durch folgende Schritte:
Aus einem genomischen Duplex-DNA-Molekül werden nukleotide Bestimmungsstellen mit mehr als etwa 20 Nukleotiden identifiziert, die entweder etwa wenigstens 65% Grundanteile von Purin oder etwa wenigstens 65% Grundanteile von Pyrimidin enthalten; und
die synthetischen, zu den identifizierten Bestimmungsstellen komplementären Oligonukleotide werden künstlich hergestellt, wobei die synthetischen Oligonukleotide ein G aufweisen, wenn die komplementäre Lage in dem Duplex-DNA-Molekül ein GC-Basenpaar hat, und ein T aufweisen, wenn die komplementäre Lage in dem Duplex-DNA-Molekül ein AT-Basenpaar hat.
2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß wenigstens ein T der Oligonukleotide durch eine Zusammensetzung ersetzt wird, die aus X, halogenierten Ableitungen von X, I und halogenierten Ableitungen von I ausgewählt ist.
3. Verfahren nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß wenigstens ein G der Oligonukleotide durch eine halogenierte Ableitung von G ersetzt wird.
4. Verfahren nach einem der vorangehenden Ansprüche, dadurch gekennzeichnet, daß wenigstens ein Grundanteil der Oligonukleotide bei der 2'-furanosen Lage durch eine nicht geladene umfangreiche Gruppe ersetzt wird.
5. Verfahren nach Anspruch 4, dadurch gekennzeichnet, daß die nicht geladene umfangreiche Gruppe aus einem verzweigten Alkyl, einem Zucker und einem verzweigten Zucker ausgewählt wird.
6. Verfahren nach einem der vorangehenden Ansprüche, dadurch gekennzeichnet, daß die Hauptkette der Oligonukleotide ein analoges Phosphodiester ist, das durch Zellulär-Zellbildung nicht vollständig hydrolysiert ist.
7. Verfahren nach Anspruch 6, dadurch gekennzeichnet, daß das analoge Phosphodiester aus einem Phosphorothiotat, einem Phosphoresenoat, einem Methylphosphat, einem Phosphoramidit, einem Phosphotriester und dem Alpha-Enantiomer von natürlich auftretendem Phosphodiester ausgewählt wird.
8. Verfahren nach einem der vorangehenden Ansprüche, dadurch gekennzeichnet, daß es zusätzlich einen Verbinder bei einem Terminus der Oligonukleotide enthält.
9. Verfahren nach Anspruch 8, dadurch gekennzeichnet, daß das Oligonukleotid außerdem eine modifizierende, dem Verbinder zugeordnete Gruppe enthält, wobei die modifizierende Gruppe das Duplex-DNA-Molekül bindet und aus einem Interkalator, einem eine Vertiefung bindenden Molekül, einem kationischen Amin und einem kationischen Polypeptid ausgewählt wird.
10. Verfahren nach Anspruch 8, dadurch gekennzeichnet, daß das Oligonukleotid außerdem eine modifizierende, dem Verbinder zugeordnete Gruppe enthält, wobei die modifizierende Gruppe das DNA zerstört und aus einem katalytischen Oxydans, einem Stickstoff-Gas, einem Alkylator, einem photochemischen Vernetzer, einem photochemischen Sensibilisator eines Singulett-Sauerstoffs und einer Reagenz ausgewählt wird, die eine direkte photochemische Zerstörung ermöglicht.
11. Verfahren nach Anspruch 10, dadurch gekennzeichnet, daß der photochemische Sensibilisator des Singulett-Sauerstoffs Eosin, blaues Methylen, orangenes Acridin oder ein 9-Amino-Acridin ist.
12. Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß die Reagenz ein Ithidium oder eine Pyren-Ableitung ist.
13. Verfahren nach Anspruch 10, dadurch gekennzeichnet, daß die modifizierende Gruppe aus einem Eosin-Isothiocyanat, einer Psoralin-Ableitung und einer Metall-Chelatverbindung ausgewählt wird.

EP 0 375 408 B1

14. **Synthetisches oligonukleotid für die Verbindung mit identifizierten Bestimmungsstellen auf Duplex-DNA-Molekülen durch Formen eines kollinearen Triplex, wenn die Bestimmungsstellen entweder ungefähr wenigstens 65% Purin-Grundanteile oder etwa wenigstens 65% Pyrimidin-Grundanteile enthält, gekennzeichnet durch folgende Merkmale:**
- 5 Eine Nukleotidfolge mit etwa 20 bis 40 Nukleotiden;
- 10 die Nukleotidfolge enthält G und T, wobei G anwesend ist, wenn die komplementäre Lage in dem Duplex-DNA ein GC-Basenpaar ist, und T anwesend ist, wenn die komplementäre Lage in dem Duplex-DNA ein AT-Basenpaar ist;
- 15 und die Folge aus einem Oligonukleotid ausgewählt wird, das bei 3' bis 5' orientiert ist und sich antiparallel mit dem ungefähr wenigstens 65% Purinanteil in den Duplex-DNA-Bestimmungsstellen und ein Oligonukleotide enthält, das bei 5' bis 3' orientiert ist und sich parallel mit dem ungefähr wenigstens 65% Purin-Fluß in den Duplex-DNA-Bestimmungsstellen verbindet.
15. **Synthetisches Oligonukleotid nach Anspruch 14, dadurch gekennzeichnet, daß die Nukleotid-Folge von gleicher Oligonukleotid-Länge zu den Bestimmungsstellen ist.**
16. **Synthetisches Oligonukleotid nach Anspruch 14 oder 15, dadurch gekennzeichnet, daß es eine Dissoziations-Konstante von 6×10^{-10} bis $1,5 \times 10^{-7}$ Mol hat.**
- 20 17. **Synthetisches Oligonukleotid nach Anspruch 16, dadurch gekennzeichnet, daß es eine Dissoziations-Konstante von etwa 10^{-9} bis 10^{-8} Mol hat.**
- 25 18. **Synthetisches Oligonukleotid nach Anspruch 14, dadurch gekennzeichnet, daß wenigsten ein T durch eine Verbindung ersetzt wird, die aus X, halogenierten Ableitungen von X, I und halogenierten Ableitungen von I ausgewählt ist.**
19. **Synthetisches Oligonukleotid nach Anspruch 14, dadurch gekennzeichnet, daß wenigstens ein G durch eine halogenierte Ableitung von G ersetzt ist.**
- 30 20. **Synthetisches Oligonukleotid nach Anspruch 14, dadurch gekennzeichnet, daß wenigstens ein Grundanteil bei der 2'-Furanose-Lage durch eine nicht geladene umfangreiche Gruppe ersetzt ist.**
- 35 21. **Synthethisches Oligonukleotid nach Anspruch 20, dadurch gekennzeichnet, daß die nicht geladene umfangreiche Gruppe aus einem verzweigten Alkyl, einem Zucker und einem verzweigten Zucker ausgewählt ist.**
22. **Synthetisches Oligonukleotid nach Anspruch 14, dadurch gekennzeichnet, daß die Hauptkette ein analoges Phosphodiester ist, der nicht vollständig durch eine Zellulär-Nuklease hydrolysiert ist.**
- 40 23. **Synthetisches Oligonukleotid nach Anspruch 22, dadurch gekennzeichnet, daß das analoge Phosphodiester aus Phosphorothioat, Phosphoroselenoat, Methyl-Phosphat, Phosphoramidit, Phosphotriester und dem Alpha-Enantiomer eines natürlich auftretenden Phosphodiester ausgewählt ist.**
- 45 24. **Synthetisches Oligonukleotid nach Anspruch 14, dadurch gekennzeichnet, daß es zusätzlich eine Verbindung bei einem Terminus enthält.**
25. **Synthetisches Oligonukleotid nach Anspruch 24, dadurch gekennzeichnet, daß der Verbinde dem 3'-Terminus zugeordnet und aus einem analogen Grundstoff mit einem Primär-Amin ausgewählt ist, das über eine Alkylverbindung und einen analogen Grundstoff mit einen Sulfhydryl, der mit der Basisebene über eine Alkylverbindung verbunden ist, verbunden ist .**
- 50 26. **Synthetisches Oligonukleotid nach Anspruch 24, dadurch gekennzeichnet, daß die Verbindung dem 5'-Terminus zugeordnet und ausgewählt ist aus einem analogen Grundstoff mit einem primären Amin, das über eine Alkylverbindung der Basisebene zugeordnet ist, sowie einem analogen Grundstoff mit einem Sulfhydryl, das über eine Alkylverbindung der Grundstoffebene zugeordnet ist, wobei eine lange Aminkette direkt mit der 5'-Hydroxyl-Gruppe des Oligonukleotid gekuppelt ist und eine lange Thiolkette direkt mit der 5'-Hydroryl-Gruppe des Oligonukleotid gekuppelt ist.**

EP 0 375 408 B1

27. Synthetisches Oligonukleotid nach einem der Ansprüche 24, 25 oder 26, dadurch gekennzeichnet, daß es zusätzlich eine der Verbindung zugeordnete modifizierende Gruppe enthält, wobei die modifizierende Gruppe das Duplex-DNA-Molekül bindet und aus einem Interkalator, einem Vertiefungs-bindenden Molekül, einem kationischen Amin und einem kationischen Polypeptid ausgewählt ist.

28. Synthetisches Oligonukleotid nach einem der Ansprüche 24, 25 oder 26, dadurch gekennzeichnet, daß es zusätzlich eine dem Verbinder zugeordnete modifizierende Gruppe enthält, wobei die modifizierende Gruppe das DNA stört und aus einem katalytischen Oxydans, einem Stickstoff-Gas, einem Alkylator, einem photochemischen Querverbindner, einem photochemischen Sensibilisator eines Singulett-Sauerstoffs und einer Reagenz ausgewählt ist, die eine direkte photochemische Störung ermöglicht.

29. Synthetisches Oligonukleotid nach Anspruch 28, dadurch gekennzeichnet, daß der photochemische Sensibilisator des Singulett-Sauerstoffs Eosin, blaues Methylen, orangenes Acridin oder ein 9-Amino-Acridin ist.

30. Synthetisches Oligonukleotid nach Anspruch 28, dadurch gekennzeichnet, daß die Reagenz Ethidium oder eine Pyren-Ableitung ist.

31. Synthetisches Oligonukleotid nach Anspruch 28, dadurch gekennzeichnet, daß die modifizierende Gruppe von einem Eosin-Isothiocyanat, einer Psoralin-Ableitung und einer Metall-Chelatverbindung ausgewählt ist.

32. Synthetisches Oligonukleotid nach Anspruch 14 für eine Applikation mit einem ausreichendem Betrag für eine zelluläre Aufnahme und eine Bindung mit den Bestimmungsstellen für eine Verhinderung eines Anwachsens von Zellen, dadurch gekennzeichnet, daß die Bestimmungsstellen in dem DNA-Gebiet benachbart zu dem RNA-Übertragungs-Ursprung liegen.

33. Synthetisches Oligonukleotid nach Anspruch 32, dadurch gekennzeichnet, daß die Zellen Krebszellen sind und das synthetische Oligonukleotid spezifisch zu dem C-myc-Gen ist.

34. Synthetisches Oligonukleotid nach Anspruch 33, dadurch gekennzeichnet, daß das synthetische Oligonukleotid ausgewählt ist aus:
3'-TGGTGTGTTGGGTTTGTGGGGGGGTGGGGGGGGTTTTTGTTGGGTGGG-5',
5'-TGGTGTGTTGGGTTTGTGGGGGGGTGGGGGGGGTTTTTGTTGGGTGGG-3',
5'-GTGGTGGGGTGGTTGGGGTGGGTGGGGTGGGTGGGTGGG-3,
3'-GTGGTGGGGTGGTTGGGGTGGGTGGGTGGGTGGG-5',
3'-GGTTGGGTGGGTGGGGTGGGTGGGTGGGTGGG-5',
5'-GGTTGGGTGGGTGGGGTGGGTGGGTGGG-3',
3'-TTTGGTGTGGGGGTGGGGGTTTGTTTTGT-5' und
5'-TTTGGTGTGGGGGTGGGGGTTTGTTTTGT-3'.

35. Synthetisches Oligonukleotid nach Anspruch 34, dadurch gekennzeichnet, daß das Oligonukleotid einen Verbinder und eine modifizierende Gruppe enthält.

36. Synthetisches Oligonukleotid nach Anspruch 14 für eine Applikation in einem ausreichenden Betrag für eine zelluläre Aufnahme und eine Verbindung mit den Bestimmungsstellen zur Verhinderung des Anwachsens von Krankheitserregern, dadurch gekennzeichnet, daß die Bestimmungsstellen innerhalb des nukleischen Säurebereiches, der an die ursprüngliche RNA-Transkription angrenzt, abbinden.

37. Synthetisches Oligonukleotid nach Anspruch 36, dadurch gekennzeichnet, daß der Krankheitserreger ein HIV-1-Virus und das synthetische Oligonukleotid innerhalb des Virus-LTR-Bereiches ist.

38. Synthetisches Oligonukleotid nach Anspruch 37, dadurch gekennzeichnet, daß das synthetische Oligonukleotid ausgewählt ist aus:
5'-TTTTGTTTGGGGGGTGTGGTTGGG-5',
3'-TTTTGTTTGGGGGGTGTGGTTGGG-5',
5'-TGTGTTGGTTGTGGGGTTTGTGGGTGTGTT-3'.

EP 0 375 408 B1

- 5 3'-TGTGTTGGTTGTGGGGTTTGTGGTGTGTT-5',
5'-GGGTGGTGGTGGTGGGGGTGTTGTTG-3',
3'-GGGTTGGTGGTGGGGGTGTTGTTG-5',
3'-TGGGTGGGGTGGGGTGGGGGGGTGTGCCCTCTGGGG-5',
5'-GTTTTGGGTGTTGTGGGTGTGTTG-3',
3'-GTTTTGGGTGTTGTGGGTGTGTTG-5' und
5'-TGGGTGGGGTGGGGTGGGGGGGTGTGGGTGTGGGG-5'.

10 39. Synthetisches Oligonukleotid nach Anspruch 38, dadurch gekennzeichnet, daß das Oligonukleotid
einen Verbinder und eine modifizierende Gruppe enthält.

15 40. Synthetisches Oligonukleotid nach Anspruch 14 für die Applikation in einem ausreichendem Betrag für
eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um den strukturellen Protein-Inhalt
des Haut-Gewebes zu manipulieren.

20 41. Synthetisches Oligonukleotid nach Anspruch 40 für eine Verhinderung eines Kollagen-Gen, dadurch
gekennzeichnet, daß das synthetische Oligonukleotid ausgewählt ist aus:
3'-TGGGTGGGTGGTGGTGGGGGTGGTTGGGGTTGG-5',
3'-GGGTTGGGTGTGGTTGGGGTGGGGTTGG-5' und
3'-GTGGTGGGTGGTGGTGGGGGTGTGGTTGG-5'.

25 42. Synthetisches Oligonukleotid nach Anspruch 40 für die Verhinderung einer Kollagenasen-Gen, dadurch
gekennzeichnet, daß das synthetische Oligonukleotid ausgewählt ist aus:
5'-GGTTGGGGTGGGTGTGTTTTTGTTGTGGGTG-3' und
5'-TTGTGGTTGTTTTGGTTGTGTGTTG-3'.

30 43. Synthetisches Oligonukleotid nach Anspruch 14 für die Applikation in einem ausreichenden Betrag für
eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um permanent eine Gen-Expression
zu verhindern.

35 44. Synthetisches Oligonukleotid nach Anspruch 14 für eine Applikation in einem ausreichenden Betrag für
eine zelluläre Aufnahme und eine Bindung mit den Bestimmungsstellen, um die Merkmale der
Muskelproteine in tierischen Nahrungsmitteln zu verändern.

40 45. Synthetisches Oligonukleotid nach Anspruch 44, dadurch gekennzeichnet, daß das synthetische
Oligonukleotid ausgewählt ist aus:
5'-TTTTTTGGGTGGGGGGGGGGGGGGGG-3'.

45 46. Synthetisches Oligonukleotid nach Anspruch 14 für eine Applikation mit einem ausreichenden Betrag
für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um den Interleukin-2-alpha-
Kettenrezeptor zu verhindern.

50 47. Synthetisches Oligonukleotid nach Anspruch 46 für die Verhinderung eines Interleukin-2-alpha-Kettenre-
zeptors, dadurch gekennzeichnet, daß das synthetische Oligonukleotid ausgewählt ist aus:
5'-TTGGGGTGGGGTTGTGGGTGTGGTTT-3' und
3'-TTGGGGTGGGGTTGTGGGTGTGGTTT-5'.

55 48. Synthetisches Oligonukleotid nach Anspruch 14 für eine Applikation in einem ausreichenden Betrag für
eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um eine Plaque-Formation in der
Alzheimer-Krankheit zu dispergieren.

55 49. Synthetisches Oligonukleotid nach Anspruch 48 zum Dispergieren der Plaque-Formation in der Alzhei-
mer-Krankheit, dadurch gekennzeichnet, daß das synthetische Oligonukleotid ausgewählt ist aus:
5'-TTTTTGTTGTTTCTTTCTTTCTTT-3',
3'-TTTTTGTTGTTTCTTTCTTTCTTTCTTT-5',
3'-TGGTGGGGGTTGGTGGTTGGTTGGTGT-5',
5'-TGGTGGGGGTTGGTGGTTGGTTGGTGT-3',
3'-TTGTGTTGTGGTGGTTGGGTGGGGTGGTGTGG-5',

EP 0 375 408 B1

50. Synthetisches Oligonukleotid nach Anspruch 14 für eine Applikation mit einem ausreichenden Betrag
für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um die Expression des
15 krankhaften Wachstums der Genfaktoren zu unterdrücken.

51. Synthetisches Oligonukleotid nach Anspruch 50 für eine Unterdrückung der Expression des krankhaften
Anstiegs der Genfaktoren, dadurch gekennzeichnet, daß das synthetische Oligonukleotid ausgewählt
ist aus:
20 3'-TGGTGGGGGTTGGTGGTTGGTGGTGT-5',
 5'-TGGTGGGGGTTGGTGGTTGGTGGTGT-3',
 3'-TGGGTGGTGGTGGGGGGTGGGTGGG-5',
 5'-TGGGTGGTGGTGGGGGGTGGGTGGG-3',
 3'-TTGTGGTGGTGGTGTGGTGGTGGGGTTGGTGGTGG-5',
25 5'-TTGTGGTGGTGGTGTGGTGGTGGGGTTGGTGGTGG-3',
 3'-TTGTGGTGGGTGGTGGTGGGTGGTGGTGGTGT-5' und
 5'-TTGTGGTGGGTGGTGGTGGGTGGTGGTGGTGT-3'.

52. Synthetisches Oligonukleotid nach Anspruch 14 für die Applikation mit einem ausreichenden Betrag für
30 eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um die Glutathion-s-Transferase pi
Gen zu unterdrücken.

53. Synthetisches Oligonukleotid nach Anspruch 52 für eine Unterdrückung der Glutathion-s-Transferase pi
Gen, dadurch gekennzeichnet, daß das synthetische Oligonukleotid ausgewählt ist aus:
35 5'-GTGTGTGGTGTGGGGGGTGGGGGGGGGG-3',
 3'-GTGTGTGGTGTGGGGGGTGGGGGGGGGG-5',
 5'-GGGGTGGTGGGTTGTGGGTTTG-3',
 3'-GGGGTGGTGGGTTGTGGGTTTG-5',
 5'-TTTTTTTTTTTTTTTTTTTTTTTTTT-3' und
40 3'-TTTTTTTTTTTTTTTTTTTTTTTTTT-5'.

54. Synthetisches Oligonukleotid nach Anspruch 14 für eine Applikation mit einem ausreichenden Betrag
für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um in dem Programm der
Cholesterin-Synthese zu intervenieren durch eine Modulation der Transkription des Enzyms, das die
45 Rate bestimmt, die den Schritt in der Cholesterin-Biosynthese, bekannt als HMGCoA-Reduktase,
begrenzt.

55. Synthetisches Oligonukleotid nach Anspruch 54 für eine Modulation der Transkription des Enzyms, das
den die Rate begrenzenden Schritt in der Cholesterin-Biosynthese bestimmt, die als HMGCoA-
50 Reduktase bekannt ist, dadurch gekennzeichnet, daß das synthetische Oligonukleotid ausgewählt ist
aus:
 3'-GGGTGGTGGTGGTGGGGGGTGGGGGGGG-5',
 5'-GGGTGGTGGTGGTGGGGGGTGGGGGGGG-3',
 5'-GGGTGGGTGGTGGGGGGGGTGGGGGGGG-3',
55 3'-GGGTGGGTGGTGGTGGGGGGGGTGGGGGGGG-5',
 3'-TGGGGTGGGTGGTGGTGGTGGGGGGGGGG-5' und
 5'-TGGGGTGGGTGGTGGTGGTGGGGGGGGGG-3'.

EP 0 375 408 B1

EP 0 375 408 B1

63. Kolineares Triplex gemäß Anspruch 62, dadurch gekennzeichnet, daß die Oligonukleotid-Länge der Bestimmungsstellen gleich derjenigen des synthetischen Oligonukleotid ist.
- 5 64. Synthetisches Oligonukleotid, das nach einem Verfahren gemäß einem der Ansprüche 1 - 13 gewinnbar ist, für die Applikation mit einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen für eine Verhinderung des Anwachsens der Zellen, dadurch gekennzeichnet, daß die Bestimmungsstellen in dem DNA-Gebiet positioniert werden, das benachbart zu dem RNA-Transkriptions-Ursprung liegt.
- 10 65. Synthetisches Oligonukleotid, das durch ein Verfahren nach einem der Ansprüche 1 - 13 gewinnbar ist, für die Applikation mit einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen zur Verhinderung des Anwachsens von Krankheitserregern, dadurch gekennzeichnet, daß die Folge in einem nukleischen Säuregebiet bindet, das benachbart zu dem RNA-Transkriptions-Ursprung liegt.
- 15 66. Synthetisches Oligonukleotid, das durch ein Verfahren gemäß einem der Ansprüche 1 - 13 gewinnbar ist, für die Applikation in einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so den strukturellen Proteininhalt des Hautgewebes zu berechnen.
- 20 67. Synthetisches Oligonukleotid, das durch ein Verfahren gemäß einem der Ansprüche 1 - 13 gewinnbar ist, für die Applikation mit einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so permanent eine Gen-Expression zu verhindern.
- 25 68. Synthetisches Oligonukleotid, das durch ein Verfahren nach einem der Ansprüche 1 - 13 gewinnbar ist, zur Applikation mit einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so die Eigenschaften der Muskelproteine in tierischen Lebensmitteln zu ändern.
- 30 69. Synthetisches Oligonukleotid, hergestellt durch ein Verfahren nach einem der Ansprüche 1 - 13 für eine Applikation in einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so den Interleukin-2-alpha-Kettenrezeptor zu verhindern.
- 35 70. Synthetisches Oligonukleotid, hergestellt durch ein Verfahren nach einem der Ansprüche 1 - 13 für eine Applikation mit einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so eine Plaque-Formation in der Alzheimer-Krankheit zu dispergieren.
- 40 71. Synthetisches Oligonukleotid, hergestellt durch ein Verfahren nach einem der Ansprüche 1 - 13 für eine Applikation in einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so die Expression der Haut-Wachstumsfaktor-Gene zu unterdrücken.
72. Synthetisches Oligonukleotid, hergestellt durch ein Verfahren nach einem der Ansprüche 1 - 13 für eine Applikation in einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so die Glutathion-s-Transferase pi Gen zu unterdrücken.
- 45 73. Synthetisches Oligonukleotid, hergestellt durch ein Verfahren nach einem der Ansprüche 1 - 13 für eine Applikation in einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so in dem Programm der Cholesterol-Synthese zu intervenieren, und zwar durch Modulation der Transkription des Enzyms, das den Schritt in der Begrenzung der Rate in der Cholesterol-Biosynthese bestimmt, die als HMGCoA-Reduktase bekannt ist.
- 50 74. Synthetisches Oligonukleotid, hergestellt durch ein Verfahren nach einem der Ansprüche 1 - 13, für eine Applikation in einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so die Expression des Nerven-Wachstumsfaktor-Rezeptors zu unterdrücken.
75. Synthetisches Oligonukleotid, hergestellt durch ein Verfahren nach einem der Ansprüche 1 - 13, für die Applikation in einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so die Virus-Replikation des Herpes-Simplex-Virus 1 anzuhalten.

76. Synthetisches Oligonukleotid, hergestellt durch ein Verfahren nach einem der Ansprüche 1 - 13, für eine Applikation in einem ausreichenden Betrag für eine zelluläre Aufnahme und Bindung mit den Bestimmungsstellen, um so die Beta-Globin-Gen-Synthese in thalassermischen und Sichel-Zellen-Anämien zu unterdrücken.

5

Revendications

1. Méthode de préparation d'un oligonucléotide synthétique qui se lie à une séquence cible d'un ADN bicaténaire, formant un complexe tricaténaire colinéaire en se liant dans le grand sillon, méthode comprenant les étapes consistant à :
 - 10 identifier à l'intérieur de l'ADN bicaténaire génomique une séquence nucléotidique cible de plus de 20 nucléotides environ, ayant un contenu en bases puriques d'au moins 65 % environ ou en bases pyrimidiques, d'au moins 65 % environ ; et
 - 15 synthétiser l'oligonucléotide synthétique complémentaire de la séquence cible identifiée, l'oligonucléotide synthétique contenant un G, quand une paire de base GC est présente à la position complémentaire dans l'ADN bicaténaire, et contenant un T quand une paire de base AT est présente à la position complémentaire dans l'ADN bicaténaire.
2. Méthode selon la revendication 1, dans laquelle au moins un T de l'oligonucléotide est remplacé par un composé choisi parmi X, des dérivés halogénés de X, I et des dérivés halogénés de I.
- 20 3. Méthode selon la revendication 1 ou la revendication 2, dans laquelle au moins un G de l'oligonucléotide est remplacé par un dérivé halogéné de G.
- 25 4. Méthode selon l'une quelconque des revendications précédentes dans laquelle au moins une base de l'oligonucléotide est substituée, en position 2' du furanose, par un groupement volumineux non chargé.
5. Méthode selon la revendication 4, dans laquelle le groupement volumineux non chargé est choisi parmi un groupement alkyle ramifié, un sucre et un sucre ramifié.
- 30 6. Méthode selon l'une quelconque des revendications précédentes, dans laquelle le squelette de l'oligonucléotide est un analogue phosphodiester qui n'est pas aisément hydrolysé par les nucléases cellulaires.
- 35 7. Méthode selon la revendication 6, dans laquelle l'analogue phosphodiester est choisi parmi le phosphorothioate, phosphoroséléniate, méthylphosphate, phosphoramidite, phosphotriester et l' α -énan-tiomère du phosphodiester naturel.
8. Méthode selon l'une quelconque des revendications précédentes, incluant également un linker à une extrémité de l'oligonucléotide.
- 40 9. Méthode selon la revendication 8, dans laquelle l'oligonucléotide comprend également un groupe modifiant attaché au linker, où le groupe modifiant se lie à l'ADN bicaténaire et est choisi parmi un intercalant, une molécule se liant dans le sillon, une amine cationique et un polypeptide cationique.
- 45 10. Méthode selon la revendication 8, dans laquelle l'oligonucléotide comprend également un groupe modifiant attaché au linker, dans lequel le groupe modifiant endommage l'ADN et est choisi parmi un oxydant catalytique, une moutarde à l'azote, un agent alkylant, un réticulant photochimique, une substance photochimique productrice d'oxygène singulet et un réactif capable de provoquer directement des dommages photochimiques.
- 50 11. Méthode selon la revendication 10, dans laquelle la substance photochimique productrice d'oxygène singulet est l'éosine, le bleu de méthylène, l'acridine orange, ou la 9-aminoacridine.
- 55 12. Méthode selon la revendication 11, dans laquelle le réactif est l'éthidium ou un dérivé du pyrène.
13. Méthode selon la revendication 10, dans laquelle le groupe modifiant est choisi parmi un isothiocyanate d'éosine, un dérivé du psoralène et un chélate de métal.

EP 0 375 408 B1

14. Oligonucléotide synthétique destiné et adapté pour se lier à une séquence cible identifiée dans l'ADN bicaténaire, afin de former un complexe tricaténaire colinéaire lorsque la séquence cible est formée d'au moins environ 65 % de bases puriques ou d'au moins environ 65 % de bases pyrimidiques, comprenant :
- 5 une séquence nucléotidique contenant entre environ 20 à 40 nucléotides ;
la séquence nucléotidique contenant G et T, dans laquelle G est présent lorsqu'à la position complémentaire de l'ADN bicaténaire se trouve une paire de bases GC et T est présent lorsqu'à la position complémentaire dans l'ADN bicaténaire se trouve une paire de bases AT ; et
la séquence étant choisie à partir d'un oligonucléotide orienté de 3' en 5' et se liant dans la direction antiparallèle au brin formé d'environ 65 % de purines au moins dans la séquence cible de l'ADN bicaténaire et un oligonucléotide orienté de 5' en 3' et se liant dans la direction parallèle au brin formé d'environ 65 % de purines au moins dans la séquence cible de l'ADN bicaténaire.
15. Oligonucléotide synthétique selon la revendication 14, dans lequel la séquence nucléotidique a la même longueur que la séquence cible.
16. Oligonucléotide synthétique selon la revendication 14 ou la revendication 15 ayant une constante de dissociation de 6×10^{-10} à $1,5 \times 10^{-7}$ molaire.
17. Oligonucléotide synthétique selon la revendication 16 ayant une constante de dissociation d'environ 10^{-9} à 10^{-8} molaire.
18. Oligonucléotide synthétique selon la revendication 14, dans lequel au moins un T est remplacé par un composé choisi parmi X, des dérivés halogénés de X, I et des dérivés halogénés de I.
19. Oligonucléotide synthétique selon la revendication 14, dans lequel au moins un G est remplacé par un dérivé halogéné de G.
20. Oligonucléotide synthétique selon la revendication 14, dans lequel au moins une base est substituée à la position 2' du furanose par un groupement volumineux non chargé.
21. Oligonucléotide synthétique selon la revendication 20, dans lequel le groupement volumineux non chargé est choisi parmi un groupement alkyle ramifié, un sucre et un sucre ramifié.
22. Oligonucléotide synthétique selon la revendication 14, dans lequel le squelette est un analogue phosphodiester qui n'est pas aisément hydrolysé par les nuclease cellulaires.
23. Oligonucléotide synthétique selon la revendication 22, dans lequel l'analogue phosphodiester est choisi parmi le phosphorothioate, phosphoroséléniate, méthylphosphate, phosphoramidite, phosphotriester et l' α -énanthiomère du phosphodiester naturel.
24. Oligonucléotide synthétique selon la revendication 14, incluant également un linker à une extrémité.
25. Oligonucléotide synthétique selon la revendication 24, dans lequel le linker est attaché à l'extrémité 3' et est choisi parmi un analogue de base avec une amine primaire fixée au plan de la base par une liaison alkyle et un analogue de base avec un groupement sulfhydryle fixé au plan de la base par une liaison alkyle.
26. Oligonucléotide synthétique selon la revendication 24, dans lequel le linker est attaché à l'extrémité 5' et est choisi parmi un analogue de base avec une amine primaire fixée au plan de la base par une liaison alkyle, un analogue de base avec un groupement sulfhydryle fixé au plan de la base par une liaison alkyle, une longue chaîne amine couplée directement au groupement hydroxyle en 5' de l'oligonucléotide et une longue chaîne thiol couplée directement au groupement hydroxyle en 5' de l'oligonucléotide.
27. Oligonucléotide synthétique selon l'une quelconque des revendications 24, 25 ou 26, contenant également un groupe modifiant, fixé au linker, dans lequel le groupe modifiant se lie à l'ADN bicaténaire et est choisi parmi un intercalant, une molécule se liant dans le sillon, une amine cationique

EP 0 375 408 B1

et un polypeptide cationique.

5'-TGGGTGGGGTGGGTGGGGGGGTGTGGGTGTGGGTG-3'.

EP 0 375 408 B1

5'-GGGGTGGGTGGGGGGGGTGGGG-3',
3'-GGGTGGGTGGGGGGGGTGGGG-5',
3'-GTGGGTGGGTGTGTGGGGGGGGGGGGTG-5' et
5'-GTGGGTGGGTGTGTGGGGGGGGGGTG-3'.

- 5 50. Oligonucléotide synthétique selon la revendication 14, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de réprimer l'expression du gène du facteur de croissance épidermique.
- 10 51. Oligonucléotide synthétique selon la revendication 50 destiné à réprimer l'expression du gène du facteur de croissance épidermique, où l'oligonucléotide synthétique est choisi parmi :
3'-TGGTGGGGTTGGTGGTTGGTGTG-5',
5'-TGGTGGGGTTGGTGGTTGGTGTG-3',
3'-TGGTGGTGGTGGTGGGGGGTGGGTGGG-5',
15 5'-TGGTGGTGGTGGTGGGGGGTGGGTGGG-3',
3'-TTGTGGTGGTGGTGGTGGTGGGGTTGGTGGTGG-5',
5'-TTGTGGTGGTGGTGGTGGTGGGGTTGGTGGTGGTGG-3',
3'-TTGTGGTGGTGGTGGTGGTGGGGTTGGTGGTGGTGG-5' et
5'-TTGTGGTGGTGGTGGTGGGGTTGGTGGTGGTGG-3'.
- 20 52. Oligonucléotide synthétique selon la revendication 14, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de réprimer le gène de la glutathion-S-transférase p.
- 25 53. Oligonucléotide synthétique selon la revendication 52, destiné à la répression du gène de la glutathion-S-transférase p, où l'oligonucléotide synthétique est choisi parmi :
5'-GTGTGTGGTGTGGGGGGTGGGGGGGGG-5',
3'-GTGTGTGGTGTGGGGGGGTTGGTGGG-5',
5'-GGGGTGGTGGGTTGTGGGTTGG-3',
30 3'-GGGGTGGTGGGTTGTGGGTTGG-5',
5'-TTTTTTTTTTTTTTTTTTTTTTTTTT-3' et
3'-TTTTTTTTTTTTTTTTTTTTTTTT-5'.
- 35 54. Oligonucléotide synthétique selon la revendication 14 destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin d'influencer la synthèse du cholestérol en modulant la transcription de l'enzyme qui détermine la vitesse de l'étape limitante dans la biosynthèse du cholestérol, à savoir la HMGCoA réductase.
- 40 55. Oligonucléotide synthétique selon la revendication 54 destiné à moduler la transcription de l'enzyme qui détermine la vitesse de l'étape limitante dans la biosynthèse du cholestérol, à savoir la HMGCoA réductase, où l'oligonucléotide synthétique est choisi parmi :
3'-GGTGTGTGGTGGTGGGGTGGGGGG-5',
5'-GGTGTGTGGTGGTGGGGGGTGGGGGG-3',
5'-GGGTGGGTGGTGTGGGGGGTTGGTGGGGGG-5',
45 3'-GGGTGGGTGGTGTGGGGGGTTGGTGGGGGG-5',
3'-TGGGGTTGGTGGTGGTTGGTGGGGGGGGTGGGGGGGG-5' et
5'-TGGGGTTGGTGGTGGTTGGTGGGGGGGG-3'.
- 50 56. Oligonucléotide synthétique selon la revendication 14, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de supprimer l'expression du récepteur du facteur de croissance nerveux.
- 55 57. Oligonucléotide synthétique selon la revendication 56 pour la suppression du gène codant pour le récepteur du facteur de croissance nerveux, où l'oligonucléotide synthétique est choisi parmi :
5'-GGGTTGTGGTGGTGGGGGGGGTGGGTGTG-3',
3'-GGGTTGTGGTGGTGGTGGGGGGGGTGGGTGTG-5',
5'-TGGGGGGGGTGGTGTGTGGGTGGGGGGTGGTGG-3',
3'-TGGGGGGGGTGGTGTGTGGGTGGGGGGTGGTGG-5',

EP 0 375 408 B1

EP 0 375 408 B1

et se lier à la séquence cible, afin d'inhiber la croissance d'organismes pathogènes dans lesquels la séquence cible se lie au niveau du domaine de l'acide nucléique adjacent à l'origine de transcription de l'ARN.

- 5 66. Oligonucléotide synthétique pouvant être obtenu par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de manipuler le contenu en protéine de structure du tissu épidermique.
- 10 67. Oligonucléotide synthétique pouvant être obtenu par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin d'inhiber l'expression du gène de façon permanente.
- 15 68. Oligonucléotide synthétique pouvant être obtenu par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de modifier les caractéristiques des protéines musculaires d'animaux de boucherie.
- 20 69. Oligonucléotide synthétique préparé par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin d'inhiber le récepteur de la chaîne alpha de l'interleukine 2.
- 25 70. Oligonucléotide synthétique préparé par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de réduire la formation de plaques dans la maladie d'Alzheimer.
- 30 71. Oligonucléotide synthétique préparé par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de réprimer l'expression du gène du facteur de croissance épidermique.
- 35 72. Oligonucléotide synthétique préparé par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de réprimer le gène de la glutathion-S-transférase p.
- 40 73. Oligonucléotide synthétique préparé par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin d'influencer la synthèse du cholestérol en modulant la transcription de l'enzyme qui détermine la vitesse de l'étape limitante dans la biosynthèse du cholestérol, à savoir la HMGCoA réductase.
- 45 74. Oligonucléotide synthétique préparé par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de supprimer l'expression du récepteur du facteur de croissance nerveux.
- 50 75. Oligonucléotide synthétique préparé par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de bloquer la réPLICATION du virus de l'Herpès Simplex de type 1.
- 55 76. Oligonucléotide synthétique préparé par une méthode selon l'une quelconque des revendications 1 à 13, destiné à être administré en quantité suffisante, de façon à être absorbé par les cellules et se lier à la séquence cible, afin de supprimer la synthèse du gène de la β -globine dans le cas de thalassémies et d'anémies falciformes.

EP 0 375 408 B1




FIG. 1A

PARALLEL

5'-----> 3' LIGAND
5'-----> 3' ORIENTING STRAND
3'-----> 5'

ANTIPARALLEL

3'-----> 5' LIGAND
5'-----> 3' ORIENTING STRAND
3'-----> 5'

FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG. 4G




FIG. 4H




FIG. 5

EP 0 375 408 B1




FIG. 6

EP 0 375 408 B1




FIG. 7

EP 0 375 408 B1





FIG. 8A

FIG. 8B

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.